Review

Frontiers of Hydroxyapatite Composites in Bionic Bone Tissue Engineering

Jingcun Shi 1,2,3,†, Wufei Dai 4,5,†, Anand Gupta 6, Bingqing Zhang 1,2,3, Ziqian Wu 1,2,3, Yuhan Zhang 1,2,3, Lisha Pan 2,3 and Lei Wang 1,2,3,*

1 Department of Oral and Maxillofacial Surgery—Head & Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
2 College of Stomatology, Shanghai Jiao Tong University, Shanghai 200011, China
3 Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, National Clinical Research Center for Oral Diseases, National Center for Stomatology, Shanghai 200011, China
4 Department of Plastic and Reconstructive Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
5 Shanghai Tissue Engineering Key Laboratory, Shanghai Research Institute of Plastic and Reconstructive Surgery, Shanghai 200011, China
6 Department of Dentistry, Government Medical College & Hospital, Chandigarh 160017, India
* Correspondence: wangleizyh@aliyun.com
† These authors contributed equally to this work.

Abstract: Bone defects caused by various factors may cause morphological and functional disorders that can seriously affect patient’s quality of life. Autologous bone grafting is morbid, involves numerous complications, and provides limited volume at donor site. Hence, tissue-engineered bone is a better alternative for repair of bone defects and for promoting a patient’s functional recovery. Besides good biocompatibility, scaffolding materials represented by hydroxyapatite (HA) composites in tissue-engineered bone also have strong ability to guide bone regeneration. The development of manufacturing technology and advances in material science have made HA composite scaffolding more closely related to the composition and mechanical properties of natural bone. The surface morphology and pore diameter of the scaffold material are more important for cell proliferation, differentiation, and nutrient exchange. The degradation rate of the composite scaffold should match the rate of osteogenesis, and the loading of cells/cytokine is beneficial to promote the formation of new bone. In conclusion, there is no doubt that a breakthrough has been made in composition, mechanical properties, and degradation of HA composites. Biomimetic tissue-engineered bone based on vascularization and innervation show a promising future.

Keywords: hydroxyapatite; composites; compound scaffolds; tissue-engineered bone; bone defect repair

1. Introduction

In repairing bone defects, autologous bone grafting has always been considered the gold standard for bone reconstruction [1]. However, autologous bone grafting can be too morbid for the patient, and the donor site is prone to various complications. In long segments of bone defects in particular, this disadvantage is more obvious [2]. Allogenic transplantation for repairing bone defects presents several issues, such as immune rejection and pathogen transmission [3]. On the contrary, tissue-engineered bone offers numerous advantages, such as minimal damage, no need to open a second surgery zone, and satisfying the demands of mechanical resistance by the recipient bone [4]. Bone tissue engineering involves transplantation of seed cells onto a scaffold with excellent biocompatibility and proper mechanical strength. Then, the cell-and-scaffold complex is implanted into the human bone defect, and various bioactive factors are added to support cell proliferation and osteogenesis to repair bone defects [5] (Figure 1).
The tissue-engineered bone was implanted into the bone defect, and then the new bone was generated and the risk of disease transmission. Tantalum and titanium as representative metal materials have excellent mechanical properties and biocompatibility, often used in the treatment of arthroplasty, joint replacement, spinal fusion, and femoral head necrosis [11,12]. Naturally derived biomaterials, such as fibrin and collagen, are produced by living organisms and eventually degrade into carbon dioxide and water. They possess good biocompatibility, come from a wide range of sources, and involve minimal adverse immune reactions [13–16]. Ceramic products, especially bioactive ceramics such as calcium phosphate ceramics (CPC),
hydroxyapatite (HA), and bioglass, have a strong bone-inducing response in addition to providing physical support [17] and are more conducive to mutual transfer with the surrounding environment [18]. However, the degradation of ceramic materials in vivo usually takes decades, and their high brittleness limits their application. Therefore, natural materials and ceramic materials are usually used to make composites with excellent properties [19].

Figure 2. Requirements for bone tissue engineering scaffold materials. Scaffold materials should be biocompatible, that is, non-toxic and harmless to cells; they should force conductivity; be degradable; be porous, used to contain cells and cytokines, and can also be used for the discharge of nutrients and metabolic waste; have mechanical compatibility, that is, having similar mechanical strength and elastic modulus with natural bone; and have the ability to load seed cells, cytokines or drugs.

HA is a primary inorganic component of natural bone and used commonly as a scaffold in artificial bone because of its good biological activity and biocompatibility [20]. Some researchers have used the MC3T3-E1 cell line for a biological assessment of commercial nano-hydroxyapatite (nHA) and found that average length of nanoparticles is around 20–40 nm. According to ISO 10993-5, nanoparticles have cyto-compatibility. In vitro micronuclei experiments demonstrated that nHA exists only in cytoplasm and extracellular space and does not penetrate the nucleus, indicating that there is no genotoxicity to cells [20]. However, HA shows low toughness and a slow rate of degradation, which does not match with the rate of bone repair [21]. HA-polymer composites have been prepared by utilizing the excellent toughness and suitable degradation rate of polymer materials. They can meet the ideal requirements of a scaffold and become a common material for bone tissue engineering [22,23]. Furthermore, with the advent of nano-molecular technology, nHA has also become an important scaffold material in bone tissue engineering [24,25]. However, both HA and nHA have a high elastic modulus and higher fragility, since a material less elastically deformed than natural bone when subject to force results in resorption of native bone [26]. Therefore, how to improve the performance of HA or nHA composite scaffolds has become a hot topic in bone tissue engineering.

2. Optimization and Improvement of HA Composite Scaffolds to Improve Osteogenic Properties

HA is a scaffold material widely used in bone tissue engineering due to its high mechanical strength and good biocompatibility. The development of nanoscience has also introduced nanotechnology into scaffold materials, promoting research on nHA. Particle size, crystalline morphology, and combining nHA with other materials promote the growth of osteoblasts and development of various biomedical materials [27]. However, HA also presents certain deficiencies as a scaffold material, such as incompatibility between the degradation rate and new bone formation and low porosity and plasticity of the scaffold. The cells have a poor ability to adhere and proliferate on HA. This leads to challenges in the progress of bone tissue engineering. In addition to the basic support function, the scaffold can also be surface-modified to improve its affinity for cells and cytokines [28].
2.1. Mimic the Composition and Mechanical Properties of Natural Bone

Bone is a natural composite material composed of organic matter (collagen) and minerals (calcium phosphate, especially HA). HA is responsible for the mechanical strength of bones, whereas the toughness and elasticity are attributed to collagen. The challenge for bone tissue engineering is to develop biomimetic composite scaffolds that balance biological and biomechanical properties [29] (Figure 3). Based on the understanding of the composition of natural bone and in-depth research, attempts are being made to prepare biomimetic materials from organic content and natural mineralized collagen [30].

Olszta et al. aligned nHA crystals along the axis of collagen fibers to mimic native bone nanostructures [31]. Some scholars also used a co-titration method of phosphate collagen (COL) solution and calcium hydroxide solution under the assistance of microwave. During in situ precipitation, collagen fibers and HA may form simultaneously. The final COL/HA biomimetic scaffold contained intra- and inter-fibrous HA [32], similar to the microstructure of natural bone. Zhou et al. developed a calcium phosphate (CaP)/Col/HA scaffold [33]. Porous CaP ceramic material simulates a porous bone structure; the second level network structure was prepared by vacuum infusion; and the tertiary HA layer was fabricated by biomimetic mineralization. This scaffold is similar in structure and composition to natural bone. The bionic scaffold formed new bone faster than a normal CaP scaffold in the dorsal muscle of the rabbit, suggesting that bionic scaffolding has improved bone induction capacity. Similarly, Cheng et al. made injectable biomimetic hydrogels using silk nanofibers (SNF) and nHA, which are similar in composition and structure to natural bones [34]. These breakthroughs can make scaffold-based bone tissue engineering safer and convenient, thus better meeting the needs of clinical application.

When the elastic modulus of tissue-engineered bone is similar to that of natural bone, the damage to autologous bone is minimal and the mechanical compatibility is the best. The compressive strength of the natural bone is 2 to 230 MPa and the elastic modulus is 0.05 to 30 GPa [35,36]. HA has sufficient mechanical strength, but its texture is brittle and lacks toughness, which leads to autologous bone resorption and limits the application of HA. The mechanical properties of the HA composites are shown in Table 1.
### Table 1. Mechanical properties of HA composites.

| Material                     | Ratio | Porosity and Pore Size | Compressive Strength (MPa) | Flexural, Tensile Strength (MPa) | Fracture Toughness (MJ/m³) | Elasticity Module (GPa) | Ref. |
|------------------------------|-------|-------------------------|----------------------------|----------------------------------|---------------------------|------------------------|------|
| Cortical bone                | -     | Porosity: 5–10%         | 100–230                    | 50–150                           | 2–12                      | 7–30                   | [35,37,38] |
| Cancellous bone              | -     | Pore size: 300–600 µm    | 2–12                       | 10–20                            | -                         | 0.5–0.05               | [35,36] |
| HA/PLA/HA                    | 8.2 (w/v) | Porosity: 63.3–78.4%    | 95                         | 161                              | 1.1                       | -                      | [39]  |
| HA/PAAm/Dex                  | -     | Porosity: 83.0%         | 34.1                       | -                                | -                         | 2.63                   | [40]  |
| HA/β-TCP                     | 1:1 (w/v) | Porosity: 84.9%         | 1.7                        | -                                | -                         | -                      | [41]  |
| nHA/CS                       | 1:50 (w/v) | Pore size < 2 µm        | 3.93                       | 8.59                             | -                         | -                      | [42]  |
| nHA/alginate/CS              | 70:18:12 (w/v) | Porosity: 81.0%       | 4.42                       | -                                | 170 (non-linked composites) | 4.8 (non-linked composites) | 13.35 | [43]  |
| PEEK/HA                      | 8:2 (w/v) | 100–400 µm; Porosity: 60.4–87.8% | 2.2–35.2                | -                                | 0.05–0.62                 | 171.7 (covalently linked composites) | [44]  |
| PEEK/HA                      | 7:1 (w/v) | -                       | 97                         | 195 (THF as the cosolvent)       | -                         | -                      | [45]  |
| Silane/HA/Gel                | -     | Porosity: 79.97–44.32%  | 2.96–13.31                 | -                                | -                         | 0.04–0.3               | [46]  |
| Aac/GO/HA/TiO₂               | -     | 107.42–256.11 µm        | 4.0                       | -                                | -                         | -                      | [47]  |
| nHA/CS-TSP                   | 7:2:1 (v/v) | Porosity: 79.96–87.55%  | 20–40                     | -                                | -                         | -                      | [48]  |
| COL-HA-MFC                   | -     | Porosities: 82.9%       | 8.7–152.4                  | -                                | -                         | -                      | [49]  |
| EC/nHA                       | -     | 70.6                    | -                         | 3.12                             | -                         | -                      | [50]  |
| PVA/CS/CHA                   | -     | 7.49                    | -                         | -                                | -                         | 0.10                   | [51]  |
| HA/PLGA                      | 9:11 (w/v) | Porosities: 60%         | 40                         | -                                | -                         | -                      | [52]  |
| Gellan/guar gum/HA           | 2:1.5:44 (w/v) | -                      | 12.662                     | -                                | -                         | -                      | [53]  |
| HA/PLGA/PGA                  | 1:9:23.33 (w/v) | Porosities: 3 µm         | 31.1                       | -                                | -                         | -                      | [54]  |
| Silk/HA                      | -     | 80, 90, 99% (w/v)       | 8.7–152.4                 | -                                | -                         | -                      | [55]  |
| nHA/CS                       | -     | 70.6                    | -                         | 3.12                             | -                         | -                      | [56]  |
| HA/PLGA/PGA                  | -     | 7.49                    | -                         | -                                | -                         | 0.10                   | [57]  |
| Cellulose-graft-polyacrylamide/nHA | - | Pore sizes: 500 µm     | 4.6                        | -                                | -                         | -                      | [58]  |
| Silk/HA                      | -     | 80, 90, 99% (w/v)       | 8.7–152.4                 | -                                | -                         | -                      | [59]  |
| PEGDA/HA                     | -     | 6.5                     | -                         | -                                | -                         | -                      | [60]  |
| HA/GCPU/CS                   | 2:3 (w/v) | Pore sizes: 80–150 µm  | 9.41                       | -                                | 0.17                      | -                      | [61]  |
| Cellulose-graft-polyacrylamide/nHA | - | Pore sizes:120–190 µm | 4.80                       | -                                | 0.29                      | -                      | [62]  |
| SA/HEC/HA                    | 40 wt% | 100–300 µm              | 23.9                       | -                                | -                         | 1.20                   | [63]  |
| TiO₂/grafted cellulose/nHA   | -     | Pore sizes: 80–150 µm   | 4.1                        | -                                | -                         | 1.20                   | [64]  |
| Mgo/nHA/PLLA                 | -     | Porosity: 60.3%         | 6.7                        | -                                | -                         | 1.20                   | [65]  |
| nHA/CS/TFSP                  | 1:9 (v/v) | Porosity: 75.4%        | 14.5                       | -                                | -                         | -                      | [66]  |

PAAm-polyacrylamide; Dex-dextran; PEEK-Polyetheretherketone; Aac-Acrylic acid; GO-graphene oxide; TSP-tamarind seed polysaccharide; MFC-Microfibrilated cellulose; EC-electrospun cellulose; PVA-poly(vinyl alcohol); CHA-carbonated hydroxyapatite; PLGA-poly(lactic-co-glycolic acid); PGA-poly(glycolide); PEGDA-poly(ethyleneglycol) diacrylate; SA-Sodium alginate; HEC-hydroxyethylcellulose; PLLA-poly(l-lactic acid); TFSP-Trigonella foenum graecum seed polysaccharide; BT-barium titanate; Ref.-Reference.
Chitosan (CS) and sodium alginate (SAL) are elastic and easy to degrade. Liao et al. [65] prepared nHA/SAL/CS composites by in situ synthesis with a compressive strength of 34.3 MPa. Some scholars constructed nHA/poly(lactic-co-glycolic acid) (PLGA)/COL scaffolds through multistage polymerization and characterized their mechanical properties. The tensile strength of the nHA/PLGA/collagen membrane was observed to be similar to that of human woven bone [66]. Over time, PLGA components gradually hydrolyze. The secreted matrix and minerals can maintain the force of the scaffolds when cultured with differentiated human mesenchymal stem cells (hMSCs). Apart from being composed of different types of materials, the ratio between materials is also very important for controlling the mechanical properties. By comparing the polymers of lactic acid (PLA)/HA composite scaffolds with different mass ratios (5:5, 4:6, 3:7, 2:8, and 1:9), it was observed that when the ratio is 8:2, the overall performance is the best in terms of a compression force and an elastic modulus of 34.1 MPa and 2.63 GPa, respectively [40]. Researchers often enhance the mechanical properties of HA by adding various polymers or monitoring the ratio of different materials, and also characterize the mechanical properties of the scaffold. Kaufman et al. produced 30 to 300 indentations on 22 polymer–ceramic composites using a nano-indentation technique [67]. A power law was used to adapt the initial unloading curve to compare the reduced elastic modulus of various materials, providing a new reference method for determining the mechanical properties of the scaffolds. Unlike metal materials, when HA composites are implanted in vivo, the mechanical strength also changes with the formation of new bone and degradation of scaffolds. Therefore, it is necessary to pay attention to the mechanical strength of the scaffold before implantation and to dynamic changes after implantation. By incorporating nanomaterials with inorganic properties, such as carbon nanotubes (CNT) [68], and by preparing biphasic calcium phosphate in different proportions with TCP, the mechanical properties of HA composites are similar to those of human cancellous bone.

2.2. Modify the Surface Morphology and Pore Size of the Material

Recent studies have shown that conventional factors may affect cellular biological properties. The morphology of the culture vessel’s surface also influences cellular growth and differentiation. The safe and effective induction of directional differentiation of BMSCs is a major task. HA discs were ground with sandpaper of various sizes. Multiple sets of surface morphology were obtained with roughness ranging from 0.2 to 1.65 µm and peak distances ranging from 89.7 to 18.6 µm. It was found that hBMSCs had the best directional adhesion and osteogenic differentiation on surfaces with an average roughness of 0.77–1.09 µm and an average peak distance of 53.9–39.3 µm [69]. Tan et al. used photolithography combined with reactive ion engraving to control the scaffold’s surface at the micro and nano scales [70]. By depositing nHA on silicone surfaces at micro and nano scales, the cells were observed to most closely resemble the morphology observed in vivo, and the cell shape was closely associated with cell growth, differentiation, and phenotypic expression. Kim et al. found that scaffolds with staggered orthogonal double-layer and alternative double-layered structures promoted cell proliferation and osteogenic differentiation [71]. Additionally, micro–nano-hybrid (the hybrid of nano-rod and micro-rod) surface topographies had better performance on osteogenic differentiation of ADSCs (adipose derived stem cells) than nanosheets and nanorods [72]. Hence, modifying the surface morphology of the scaffolds, such as roughness, micron, nano scale, or arrangement structure, will affect the properties of the cells and determine osteogenesis.

The pore size of natural cancellous bone is 300–600 µm and porosity is 75–85% [37,38]. Large pore size and porosity are conducive to nutrient delivery and metabolite excretion. A scaffold’s porosity also plays a major role in cell and cytokine penetration and inducement of bone formation. Numerous studies have shown that larger pore sizes and porosity contribute to the formation of new bone and blood vessels. In general, pore size above 50 µm facilitates the entry of cells and angiogenesis. One of the latest research studies focused on the preparation of porous scaffolding. Zhou et al. soaked melamine foam in HA/CS
composite suspension until liquid filled the foam [73]. Then, the composite material was dried by vacuum oven. As the moisture evaporated, vacuum suction guided uniform voids to form and connect with each other. The aperture range of 90–130 µm was observed. The CS and HA composites were injected into the composite braid, and porous scaffolds were prepared by freeze-drying and cold atmospheric plasma techniques. HA provides macroscopic pore size of the scaffold from 80 to 180 µm, while the cold atmospheric plasma treatment made the microscopic pore size of the scaffold ≤10 µm and the porosity of the scaffold ≥80% [74]. Dou et al. developed a PLGA/nHA/Gel scaffold. This composite scaffold featured a large front hole size of >1100 µm and a side hole of >500 µm, providing sufficient open space and reliable overall support for the growth of cells and tissues [75]. In addition to the characterization of the scaffold aperture, some in vivo/in vitro experiments were also carried out. Interconnected pores facilitated cell growth in the interior of the material. Scholars have prepared Poly (L-L-lactic acid) (PLLA) and HA scaffolds of different pore sizes. Studies have found that scaffolds with a 500–600 µm pore size promoted more osteoblast adhesion than scaffolds with a small pore size (150–315 µm and 315–400 µm) [76]. Lee et al. investigated the bone regeneration potential of nanocomposite polydopamine/HA/COL/calcium silicate scaffolds and implanted them into a rat bone defect model, finding higher new bone formation in the 500 µm pore size group than in the 250 µm group [77]. The porosity of the scaffold allows tissue growth and nutrition transfer, a finding that elicited widespread concern among researchers. Because porous structures are easily damaged at high temperatures, pore size, porosity, and mechanical strength of the scaffolds should be balanced to create load-bearing tissue-engineered bone. It is difficult to prepare a scaffold with both a porous structure and excellent mechanical properties. Therefore, it is necessary to optimize the creation process of the scaffold or to employ low temperature disinfection to tackle this problem.

2.3. Regulation of the Degradation Rate of Scaffolds

HA is a common scaffold used for bone tissue engineering and has good biocompatibility. However, the degradation rate of HA is slow, and it may last for several years. This mismatch between the degradation of the scaffold and the formation of bone seriously affects the quality of the tissue-engineered bone.

Bioactive glass is commonly used in bone tissue engineering and often used to enhance the mechanical properties. Zhang et al. prepared HA-CaO ceramics and found that the addition of CaO made the scaffold more easily degradable. They soaked the HA-CaO ceramic in Tris-buffered saline solution for 28 days. Due to the dissolution of CaO, it converted into CaCO₃. The area fraction and the size and depth of pits for composite ceramics have increased compared to pure HA ceramics [78]. Shuai et al. [79] added poly (glycolic acid) (PGA) to HA/PLLA scaffolds to accelerate degradation. After a 28-day immersion, the weight loss rate increased from 3.3% to 25.0%. Since PGA is highly hydrophilic, it degrades first and accelerates PLPA hydrolysis. Scaffold degradation promotes both exposure and deposition of HA. The scaffold was implanted into the radius bone defect of a rabbit, and the defect area was repaired after eight weeks of implantation. In addition to studying the degradation of scaffolds in solution, there are scholars who studied biological degradation under the action of cells. Some scholars have prepared Li/HA scaffolds and studied their in vitro degradation by solution and osteoblast pathways. Studies have shown that the mechanism of simulated body fluid (SBF) degradation is significantly different from that of cells. In SBF, HA is deposited on the surface after hydrolysis of the Li/HA scaffold. The degradation of the scaffold by osteoblasts is a biological phenomenon [80]. Chang et al. reported HA/CS scaffolds where the degradation of compound materials was divided into a faster (about 10 wt% per week) stage and the second stage (about 1 wt% per week), due to the faster degradation rate of CS. This scaffold was implanted into a femur bone defect of a rat. It degraded after 13 weeks of implantation, and new bone and angiogenesis were observed [81]. Organic materials such as collagen are more easily degraded than inorganic compounds such as bio-active glass and nHA. Thus, these two factors are of-
ten combined to obtain satisfactory degradation rates. In addition to organic materials, growth factors such as recombinant human bone morphogenetic protein (rhBMP2) have also been reported to promote degradation [82]. The factors influencing the degradation of scaffolds are listed in Table 2. To observe the process of HA degradation, Li et al. prepared a concentric membrane with an internal HA/terbium (TB) ring and an external ring of HA/nano-wires (NWS). The interior and exterior ring materials are fluorescent at the same time. By tracing the fluorescence distribution, HA/TB initially diffused from the internal ring, indicating that HA/TB degraded earlier than HA/NWS [83]. This provides a reference for understanding a series of behaviors such as degradation, diffusion, and reconstruction of a scaffold during bone repair. There have been relevant studies on in vitro/in vivo degradation of scaffolds, but the mechanisms related to cell degradation of scaffolds are not clear. Li et al. [84] prepared nHA/COL composite scaffolds and loaded umbilical cord MSCs. In this study, the inhibition of the Wnt/β-catenin pathway was found to lead to rapid degradation of scaffolds and delayed new bone formation. This provided insight for studying the biological degradation mechanisms of a scaffold. Extensive studies have shown that it takes about two to four months to observe new bone formation and takes up to six months to obtain histological healing [25,85–87]. Therefore, the degradation rate of scaffold materials should correspond to this rate. The degradation of materials can be adjusted by preparing cross-linked composite scaffolds and can also improve the elastic modulus of the scaffolds [88–91]. In addition, HA can be doped with metal dopants to improve their properties; for example, Mg$^{2+}$ prevents HA crystallization and reduces bone brittleness. Zn$^{2+}$ can inhibit bacterial colonization and regulate inflammatory mediators. Another metal dopant, Sr$^{2+}$, promotes bone formation by activating signaling pathways, inhibiting bone resorption and regulating cell behavior [92,93].

Table 2. Factors influencing the degradation of scaffolds.

| Scaffolds         | Parameters       | Results                                                                 | Ref.  |
|-------------------|------------------|-------------------------------------------------------------------------|-------|
| nHA/CS/Gel        | Polymer ratio    | Among the different proportion of the nHA and CS/Gel, HA80CG20 (nHA:CS/Gel = 8:2) possess the highest degradation. | [94]  |
| PHB/nHA           | Shape            | The smaller the thickness of the specimen, the higher the aspect ratio and therefore the greater surface area for the enzymes to attack. | [95]  |
| PLA/HA            | Surface area of particles | 15% PLA scaffolds filled with HA (spray dried) exhibited significantly lower mass loss rate than scaffolds filled with HA (sintered), which was possibly due to the higher surface area of particles. | [96]  |
| CS/1wt%HA(CAP)    | Porosity/pore size | Larger surface area and more active sites for the lysozyme reaction were obtained through CAP treatment, which increased the degradation rate significantly. | [75]  |
| PGA/HA/PLLA       | Hydrophilic      | The PGA enhanced the degradation rate of scaffolds as indicated by increasing the weight loss, owing to the degradation of high hydrophilic PGA. | [79]  |
| CS-g-PCL          |                  | Hydrophilic materials including copolymer and nHA were compounded with PCL to increase the degradation rate. | [97]  |
| PLGA/HA/βTCP      |                  | PLGA copolymers are less hydrophilic and lead to a slower degradation of the polymer chains. | [98]  |
Table 2. Cont.

| Scaffolds               | Parameters          | Results                                                                                                                                                                                                 | Ref.   |
|------------------------|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| PLA/HA                 | PH                  | Alkaline HA particles release OH− ions, which can neutralize the acidic degradable substances generated during the PLA degradation process. As a result, acid driven autocatalytic degradation of the polymer phase can be reduced, thus slowing degradation. | [96,99]|
| nHA/PCL/Pluronic       |                     | The nHA/PCL/Pluronic scaffold had the lowest degradation rate in pH 7.4 among three degradation media. The solution of HA particles in acidic environment accelerated the degradation of the polymer matrix just as the self-catalysis of acidic products on polyester degradation. At high pH, PCL has further advantages as it introduces OH and COOH groups on the surface, rendering hydrophilic substrates that will prove its degradation. | [100]  |
| Sr10-HA-g-PBLG         | Relative molecular weight | The molecular weight of the grafted PBLG increased with the theoretical grafting ratio. The degradation rate decreased with the increasing molecular weight of grafted PBLG. nHA increased physical crosslinkers among the polymeric materials and had the reverse impact on degradation. The scaffold sample BGH1 (contain 1.4 g nHA) showed the most degradation, while BGH3 (contain 1.6 g nHA) showed the least. | [101]  |
| ARX/BG/AAc/GO/nHA      | Physical crosslinked | Alginate strengthened the resultant hydrogel stability by increasing crosslinking densities, thus reducing the degradation rate. In the presence of CA, the weight loss of the scaffolds decreased, probably due to the increased interaction between nHA particles and CS and Gel molecules via CA functional groups. | [102]  |
| nHA/alginate/GEL       | Interactions between materials | PCL70/PHBV30/nHA5 (wt%) maintained higher degradation than PCL90/PHBV10/nHA5 (wt%), which indicated the weak interactions between two polymers. | [103]  |
| nHA/CS/Gel             |                     | GP can increase the covalent linkage between polymer chains, thereby reducing the degradation rates. Ca2+ in nHA can coordinate with the amide bond of gelatin, thereby increasing the stability of the composite hydrogel and prolonging the degradation time. | [104]  |
| PCL/PHBV/nHA           |                     | Good biocompatibility provided by the rGO can improve cell adhesion and promote the proliferation and differentiation of cells. The new bone formation permits the extrusion of new bone, which supports cell adhesion and osteogenesis. | [105]  |
| GP/nHA/HPCS            | Covalent linkage    | Composite matrix with Si/nHA presented superior biodegradation of the scaffold. | [73]   |
| GelMA/PEGDA/nHA        |                     | Good biocompatibility provided by the rGO can improve cell adhesion and promote the proliferation and differentiation of cells. | [91]   |
| HA/rGO                 | Biocompatibility    | Good biocompatibility provided by the rGO can improve cell adhesion and promote the proliferation and differentiation of cells. | [106]  |
| Si/nHA                 | Biological effect   | Silicate species released from the Si/nHA scaffold would attract osteoclast cells toward the biomaterial. | [82]   |
| CS/HA                  | Growth factors loading | RhBMP-2 and concomitant rapid material degradation synergistically promote bone repair and regeneration with CS/HA scaffolds. |        |

PHB-poly(3-hydroxybutyrate); PLA-poly(lactic acid); CAP-cold atmospheric plasma technology; PBLG-Poly(y-benzyl-l-glutamate); ARX-arabinoxylan; BG-β-glucan; CA-citric acid; PHBV-poly (hydroxybutyrate-co-hydroxyvalerate); GP-genipin; HPCS-Hydroxypropyl chitosan; GelMA-gelatin methacyrlylamine; Ref.-Reference.

2.4. HA Scaffolds Combined with Cells/Extra-Cellular Matrix/Cytokine to Promote Osteogenesis

Seed cells and cytokines are major components of bone tissue engineering. We mentioned that the porosity of the scaffold is associated with the entrance of cells and growth factors. Some scholars directly combined cytokines, cells, or extra-cellular matrix with HA, hoping to obtain better biocompatibility and osteogenic properties.
BMSCs are pluripotent stem cells that can differentiate in the direction of osteogenesis, lipolysis, and cartilage, and their ability for multi-directional differentiation also makes BMSCs the most commonly used seed cells. Wüst et al. encapsulated hBMSCs using HA/alginate/gelatin composite hydrogels and used 3D printed gel scaffolds. The scaffolds were then cultured in vitro for three days, and cellular viability was identified by fluorescent staining. Most of the cells in the material were alive, and only 15% were dead cells [107]. In addition to bone marrow, mesenchymal stem cells derived from the umbilical cord and adipose tissue were applied [4,108]. Osteoblast lines or osteoblastic progenitor cells lines such as MC3T3-E1 and MG-63 are often used in tissue-engineered bone [109,110]. Bone homeostasis is maintained by the balance of osteoblasts and osteoclasts, and current research focuses on the osteoblasts. However, previous studies have shown that osteoclasts not only absorb bone, but also regulate osteoblasts to promote osteogenesis [111]. Thus, further development of tissue-engineered bone may introduce osteoclasts to promote bone remodeling.

In tissue engineered bone, seeding of cells onto scaffold material and then implanting the cell/scaffold complex into the defect area is a common method. Some scholars have sown MG-63 osteoblasts on the surfaces of titanium, stainless steel, and collagen-coated materials with different roughness. It was found that cells on the collagen coating had more local adhesion, and the moving speed could reach 60 nm/min [110]. The increase in focal adhesions suggested that the cells have strong dynamic capacity and ECM secretion capacity. This study also suggests that an extracellular matrix may also influence the migration and osteogenesis of seed cells. Onishi et al. [112] used an osteoblast sheet to generate extracellular matrix plates that bind cytokines such as BMP-2 and transforming growth factor β1 (TGFβ1), and it was implanted into the rat femur defect site. The study found that the osteoblast extracellular matrix loaded with growth factors such as BMP2 and TGFβ1 first appeared at bone deposition, and the maximum bending load at eight weeks was significantly stronger than that of the control group, which is a rare scaffold-free extracellular matrix to repair bone defects. Over the past few years, self-assembled molecular materials have been able to effectively support the proliferation and differentiation of various cells. Self-assembling peptides are nanostructured and biomechanically similar to extracellular matrices, and can form a 3D environment for cells. This makes them suitable candidates for artificial cellular niches, which have been applied in bone tissue engineering [113,114]. Alshehri et al. mixed hBMSCs with IVZK-IVFK peptide solutions to form 3D cultures. This self-assembling peptide was found to promote osteogenesis differentiation of BMSCs [114]. Zhang et al. [115] combined self-assembled peptides with nHA/CS scaffolds, which increased BMSCs adhesion and improved the mechanical properties of the scaffolds. It was implanted into the femoral defect of a mouse, and the defect healed after 12 weeks. A large amount of trabecular bone was found in the newly formed bone. It is suggested that self-assembled peptides may promote osteogenesis and have good prospects in tissue-engineered bone.

BMP, a cytokine that induces bone formation, was extracted from human demineralized bone matrix by Urist [116]. It can regulate cell proliferation, differentiation, apoptosis, or morphogenesis and possesses various biological functions. BMP2 belongs to the first sub-type and is primarily involved in bone growth and differentiation. Many scholars combine it with scaffolds to promote the induction and differentiation of BMSCs. Su et al. [82] developed collagen/HAnano-composites and pre-absorbed rhBMP2, implanted them into the femoral defect of rabbits, and collected samples for analysis after eight weeks. Micro-CT and histological staining indicated that the scaffolds with pre-absorbed rhBMP2 could effectively repair bone defects. Bone formation occurred faster and it reached a higher degree of mineralization than the rhBMP2-free material. Composite scaffolds made of BMP2 and other materials have the capacity to promote adherence proliferation and osteogenic differentiation of cells, and they have good osteogenic induction properties [117–122]. Some scholars have also synthesized BMP-2 peptidomimetics (E7 BMP-2 peptides) [123], p24 peptides derived from BMP2 [124] and p28 peptides [109], which can also promote cell
proliferation, adherence and differentiation, and promote bone tissue formation in a dose-dependent manner. Shui et al. [125] introduced recombinant adenovirus into osteogenic progenitor cells to modulate the expression of BMP9. The BMP9-mediated C2C12 cells were found to easily develop mineralized nodules. BMP9 can indeed help differentiate C2C12 cells into osteoblasts. Meanwhile, collagen sponges loaded with BMP9-transduced C2C12 induced strong bone formation within four weeks. Apart from the BMP family, there are many other cytokines that promote osteogenesis. Liang et al. [126] used naringenin (NG) and calcitonin gene-related peptide (CGRP) in combination with HA and sodium alginate (SAL) composite hydrogel scaffolds and demonstrated that they have better biosynthesis than simple composite scaffolds in bone function. MicroCT, HE and TB staining showed a significant increase in the amount of mineralization infused with NG and CGRP. Shi et al. [127] functionalized HA with lactoferrin (LF), which could enhance cell viability and have high biocompatibility. Typical growth factors used in tissue engineering are presented in Table 3 [34,82,117–122,125,126,128–154]. More importantly, the incorporation approaches and release profiles of growth factors govern the differentiation of cells and are closely correlated with osteogenesis.

The function of cytokines has been basically clarified, and they have been extensively used in vitro and in vivo. However, the interaction mechanism and the spatial-temporal release of multiple cytokines require further exploration. Currently, the major part of the assessment of osteogenesis effects adopts histopathologic indicators given a lack of more accurate and quantitative methods, and research on the mechanism of osteogenesis is insufficient. These factors limit the clinical application of tissue-engineered bone.

Table 3. Growth factors commonly used in tissue engineering.

| Growth Factor | Scaffolds | Incorporation Approach | Release Profile | Outcomes | Ref. |
|---------------|-----------|------------------------|----------------|----------|-----|
| BMP-2         | CS/HA     | Physical entrapment/Adsorption. | Rapid burst release between 12–36 h, followed by a slower release during the following 7 days. | In vitro: RhBMP-2 and concomitant rapid material degradation synergistically promote bone repair and regeneration with CS/HA scaffolds. | [82] |
| BMP-2         | CS/HA/TiO2| Physical entrapment/Adsorption. | Rapid burst release in the first week, followed by a slower release during the following 3 weeks. | In vitro: The BMP-2 loading in CS can significantly improve cell adhesion, spreading, and proliferation. | [117] |
| BMP-2         | HA/PLL/PDA| Physical entrapment/Adsorption. | Rapid burst release in the first week, followed by a slower release during the following 2 weeks. | In vitro: The BMP2-entrapped PLL/PDA coating on the HA scaffold can promote osteogenic differentiation of BMSCs. In vivo: Induce ectopic bone formation to a much greater level in vivo compared with a bare HA scaffold that delivers BMP2 in a burst manner. | [118] |
| BMP-2         | nHA/COL   | Physical entrapment/Adsorption. | Extended sustainable release for 21 days. | In vitro: The BMP-2-nHA-COL scaffold promoted BMSCs adhesion, proliferation, and differentiation. In vivo: Increased osteoblast proliferation and osteogenic differentiation, as evidenced by metabolic activity, alkaline phosphatase activity, and calcium deposition. | [119] |
| BMP-2         | PCL/PDA/HA| Physical entrapment/Adsorption. | Approximately 20% of the BMP-2 was rapidly released within 24 h. | In vitro: The scaffold had a more profound effect on the attachment, proliferation, and osteogenic differentiation of BMSCs. | [120] |
| BMP-2         | CA/SF/PEO/nHA | Physical entrapment/Adsorption. | Rapid burst release in the first 3 days. | In vitro: Enhanced bone regeneration in vivo. | [121] |
| BMP-2         | HA/PG     | Extended sustainable release. | In vitro: Enhanced osteogenic differentiation of hADSCs. In vivo: Improved bone formation in a calvarial bone defect. | [128] |
Table 3. Cont.

| Growth Factor | Scaffolds | Incorporation Approach | Release Profile | Outcomes | Ref. |
|---------------|----------|------------------------|-----------------|----------|------|
| BMP-2         | Hyaluronan hydrogel with 25% HA | Chemically cross-linked. | Rapid burst release between day 3 and 2 weeks, followed by a slower release during the following 2 weeks. | In vivo: Improved bone formation in a rat bone defect. | [129] |
| BMP-2         | SF/CS/agarose/HA with or without bioactive glass | - | Extended sustainable release. | In vitro: Increase the ALP activity in MC3T3 preosteoblast cells. | [130] |
| BMP-2         | PELA/HA | - | A slow and sustained release. | In vitro: Promote bone formation in an ectopic muscle pouch model. | [131] |
| BMP-2         | nHA    | - | - | BMP-2 loaded can repair 5 mm bone defects in rat femora by 12 weeks. | [132] |
| BMP-2         | HAs    | Physical entrapment/Adsorption. | - | In vivo: BMP-2 anchored on the HA-Pol surface with a relative loosened conformation, while the HA-Sin surface induced a compact conformation of BMP-2. | [133] |
| BMP-2         | HA/COL | Physical entrapment/Adsorption. | - | BMP-2 can enhance bone formation in a canine sinus model. | [134] |
| BMP-2         | PCL/PVAc/PLGA/nHA | Physical entrapment/Adsorption. | Rapid burst release. | Enhance the expression of ALP, OCN, OPN. | [135] |
| BMP-2         | nHA/PLA/Gel | Utilize a polydopamine (pDA)-assisted coating to immobilize the BMP-2. | Sustained release. | In vivo: BMP-2 can enhance bone formation in a rat cranial bone defect model. | [136] |
| BMP-2         | PLLA/HA | Covalent binding. | Sustained release. | In vivo: Enhance the growth and osteogenic differentiation of BMSCs. | [137] |
| BMP-2         | SF/PEO/nHA | Physical entrapment/Adsorption. | A burst release. | In vivo: Enhanced bone regeneration at 12 weeks post-implantation. | [138] |
| BMP-2         | SF/nHA | embedded with SF microspheres. | A burst release on the first day. | In vivo: Promoted the adhesion and osteogenic differentiation of BMSCs. | [122] |
| BMP-2         | GEF    | In situ UV-crosslinking | - | In vitro: Enhanced osteo-differentiation of MSCs. | [139] |
| BMP9          | COL1/HA/TCP | Recombinant adenovirus transfect C2C12 cells to express BMP9. | - | In vitro: Induced osteogenic differentiation in C2C12 cells. | [125] |
| Growth Factor | Scaffolds            | Incorporation Approach       | Release Profile                     | Outcomes                                                                                                                                                                                                 | Ref. |
|---------------|---------------------|------------------------------|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| IGF           | PLGA/HA             | Covalent binding.            | -                                  | In vitro: Enhanced ADSCs attachment and proliferation.                                                                                                                                                      | [139]|
|               |                     |                              |                                    | Increased ALP activity and expression of osteogenesis-related genes of ADSCs.                                                                                                                                 |      |
| SDF-1         | HA                  | Physical entrapment/adsorption. | Sustained release.                | In vitro: Stimulated the migration of MSCs to the deep interior of the scaffold. Facilitated osteogenic differentiation.                                                                                      | [140]|
|               |                     |                              |                                    | In vitro: promote the formation of blood vessels and bone.                                                                                                                                                  |      |
| VEGF          | PCL/HA              |                              | -                                  | VEGF could enhance proliferation of rBMSCs. VEGF could promote the protein and mRNA expression levels of osteoblast- and endothelial cell related markers, such as OPN, COL 1, RUNX2, VEGF, vWF, CD31. | [141]|
|               |                     |                              |                                    | In vivo: VEGF could support the formation of vessels and bone.                                                                                                                                              |      |
| VEGF          | Mg/CDHA             | Covalent binding.            | A burst release in the first day.   | Promote the differentiation of MC3T3-E1 cells.                                                                                                                                                            | [142]|
| VEGF          | HA/COL              | Physical entrapment/adsorption. | -                                  | In vivo: Enhance the expression of LC3-I/LC3-II, Beclin-1, VEGF, and CD31. The new callus grew well, accompanied by remarkable angiogenesis and osteogenesis.                                                        | [143]|
| Ang2          | HA/COL              | Physical entrapment/adsorption. | -                                  | In vitro: PDGF-BB produced from BMSCs-P can enhance the migration of BMSCs. PDGF-BB facilitate angiogenesis and promote bone regeneration.                                                               | [144]|
| PDGF-BB       | PLGA/nHA            | Lentiviral vectors (LV-pdgb) were physically entrapped. | Continuous release of lentiviral vectors (LV-pdgb). | In vivo: The expression of pdgfb and the angiogenesis-related genes vWF and VEGF2 were significantly increased. PDGF-BB facilitate angiogenesis and promote bone regeneration. |      |
|               |                     |                              |                                    | In vitro: Binding efficiency of pDNA complex to MCM was quantified as 76.5%. MCM loaded with pTGF-β1 and/or pBMP-2 incorporated into cell aggregates can transfect MSCs and induce production of TGF-β1 and/or BMP-2, respectively. |      |
|               |                     |                              |                                    | TGF-β1 production was sustained within day 4. BMP-2 production was sustained between day 12 to day 16.                                                                                                       | [145]|
| TGF-β1 and BMP-2 | mineral-coated HA microparticles | pTGF-β1 and pBMP-2 are physically entrapped. | -                                  | In vitro and in vivo: Delivery of TGF-β1 and pBMP-2 resulted in chondrogenesis and osteogenesis.                                                                                                            |      |
| BMP-2         | NSF/PCL/nHA         | Carbodiimide coupling was used to load the growth factors. | A burst release over the first 3 days for both growth factors. | MSCs exist donor-to-donor variability in differentiation capacity. In vitro: Both growth factors can support cell adhesion, viability, and proliferation. Both growth factors can promote the expression of OPN, BSP, osteonectin, and collagen I, while BMP-2 can elevate the expression of Runx2, OCN, and ALP. Boost differentiation among the seeded osteogenic cells (evidenced by ALP activity and ARS staining). | [146]|

Table 3. Cont.
| Growth Factor | Scaffolds | Incorporation Approach | Release Profile | Outcomes | Ref. |
|---------------|-----------|------------------------|----------------|----------|-----|
| TGF-β1 BMP-2 | Gel microparticles and mineral-coated HA microparticles | TGF-β1 carried by Gel microparticles, while BMP-2 carried by HA microparticles. | Relatively rapid release of TGF-β1. More sustained release of BMP-2. | In vitro: TGF-β1 and BMP-2 loaded microparticles exhibited enhanced chondrogenesis and ALP activity. Staining for types I and II collagen, osteopontin, and osteocalin revealed the presence of cartilage and bone. | [147] |
| TGF BMP-2 | - | Physical entrapment/adsorption. | - | Elevated the expression of types I, II, and X collagen, suggesting defect healing via endochondral ossification. | [148] |
| SDF-1 BMP-2 | SF/nHA | SDF-1 is incorporated via physical adsorption. BMP-2 is loaded into microparticles. | Burst release of SDF-1 Sequential release of BMP-2. | In vitro and in vivo: SDF-1 can promote cell migration. BMP-2 can support cell proliferation and osteogenesis. | [149] |
| BMP-2 MEL | PLGA/CS/HA | Encapsulated in PLGA microparticles. | Sustainable release. | In vitro: Enhanced the proliferation of cells and the expressions of differentiation markers (RUNX2, ALP). In vivo: Induce BMSCs osteogenic differentiation. | [150] |
| BMP-2 OGP | PLGA/HA | BMP-2 was carried by pore-closing process and layer-by-layer (LbL) assembly technique OGP was carried by PLGA microparticles. | Sustainable and Spatio-temporal release. | Enhance ALP activity and osteogenic gene and protein (Runx2, COL I, and OCN) expression. BMP-2 makes contributions to osteogenic differentiation in an early stage while OGP accelerated proliferation and maturation of osteoblast precursors at a later stage. In vivo: Dual biofactor-loaded scaffold manifested the best repair efficacy. | [151] |
| BMP-2 VEGF | PCL/HA | Two growth factors were incorporated employing a multilayered coating based on polydopamine (PDA). O-CMCS-O-assembly technique OGP was carried by PLGA microparticles. | Sustainable and Spatio-temporal release. | Upregulation of osteogenic (RUNX-2, ALP and OCN) and angiogenic (VEGF-A, VEGF-R2 and EDH-1) markers. | [152] |
| VEGF BMP-2 | HA/COL | Carboxymethyl chitosan micropores were used to carrier rhBMP-2 and VEGF. | A burst release of VEGF, while a sustained release of BMP-2 was observed. | In vivo: rhBMP-2 could promote the formation of bone, while VEGF could efficiently promote the production and development of new blood vessels. In vitro: Double loading of DFO and BMP-2 promote vascularization optimization. | [153] |
| BMP-2 DFO | SNF/nHA | Physical entrapment/adsorption. | Extended sustainable release. | DFO and BMP-2 promoted ALP activity and the expression of levels of RUNX-2, OCN, OPN. In vivo: Improved new bone quality with both osteogenic and angiogenic features. In vitro and in vivo: Active proliferation and differentiation of BMSCs. In vivo: Accelerate the rate of new bone formation. | [34] |
| NG CGRP | HA/SA | Physical entrapment/adsorption. | - | Support the formation of bone. In vivo: Accelerate the rate of new bone formation. | [126] |
| CGF | nHA/COL | Physical entrapment/adsorption. | - | Increased the expression of OCN. Increased the BMP2 at 8 weeks. Elevate the compressive strength and elastic modulus. | [154] |

PLL-poly(L-lysine); PDA-poly dopamine; CA-cellulose acetate, PG-pyrogallol; PELA-poly(d,l-lactic acid)-co-poly(ethylene glycol)-co-poly(d,l-lactic acid); HA-hydroxyapatite surfaces; HA-Pol-crystal-coated polished surface; PCL-Poly(caprolactone); PVAc-polyvinyl acetate; PEO-poly (ethylene oxide); GEF-gelatin electrospun fibrous; CDHA-Ca-deficient hydroxyapatite; Ang-2-Angiogenesis 2; NSF-Non-mulberry silk fibro; MEL -melatonin; OGP-osteogenic growth peptide; DFO-deferoxamine, small molecule compound; SNF-silk nanofibers; NG-naringenin; CGF-concentrated growth factor; Ref.-Reference.
3. HA Compound Bioscaffolds Promote Angiogenesis

Based on bone regeneration, scholars have further investigated the vascularization of tissue-engineered bone. Regeneration of vessels can effectively transport nutrients and metabolic waste, which is of great importance in the formation of bones. Currently, there exist three primary strategies to promote vascularization: (1) seeding angiogenic cells such as endothelial cells; (2) adding cytokines that guide angiogenesis, such as vascular endothelial growth factor (VEGF), etc.; (3) through microsurgical techniques, transplanting autologous vessels to promote vascularization. The above three methods have received great attention by scholars in the vascularization of tissue-engineered bone and have been extensively utilized. The strategies of vascularization and neuralization of tissue-engineered bone are shown in Figure 4.

![Figure 4. Vascularization and neuralization of tissue-engineered bone. Natural bone contains blood vessels and nerves. Blood vessels can transport oxygen, nutrients, and metabolites, which is very important for the proliferation and differentiation of seed cells in tissue-engineered bone. Nerves can transmit sensations and secrete neurotransmitters. Tissue-engineered bone can possess sensation, which makes it more bionic. Neurotransmitters can regulate the activity of osteoblasts and osteoclasts to maintain bone homeostasis. It can also regulate the constriction and relaxation of blood vessels, which are mainly determined by the type of blood vessels. Neurotransmitters are involved in regulating the regeneration of blood vessels. The current strategies for vascularization and neuralization of tissue-engineered bones mainly include: loading vascular endothelial cells and neural stem cells; loading angiogenesis factors and nerve growth factors, which can also be transfected into cells by transfecting gene coding; implanting blood vessels, nerves, and other tissues through microsurgery.](image-url)
3.1. HA Scaffold Combined with Vascular Endothelial Cells Promotes Angiogenesis

With further research on tissue-engineered bone vascularization, scholars co-cultured angioblasts and osteoblasts and formed complex scaffolds. These experiments were extensively done and gave good results [155]. Zhang et al. [156] developed a double-cell sheet (DCS) complex consisting of osteoblast sheets and vascular endothelial cell sheets with osteogenesis and vascular formation potential. The double-layer diaphragm and coral hydroxyapatite (CHA) complex were implanted under the skin of nude mice, and it was found to have more mature mineralization and generated more capillaries after 12 weeks. The success of in vivo vascularization has brought tissue-engineered bone closer to clinical application. Vascular endothelial cells and osteoblasts participate in bone tissue engineering together, which can promote angiogenesis and improve the quality of bone [157].

The use of endothelial cells and osteoblasts, co-cultured to promote vascularization and osteogenesis, has been widely explored. Histologically, a lumen-like structure was seen, which indicated some progress in a positive direction. However, the vessels are still relatively naive, and it remains to be determined if the newly formed vessels have blood perfusion and nutrient exchange. Furthermore, some scholars have found that nHA can accumulate in vascular endothelial cells, thereby reducing the ability of cells to form blood vessels, which is a problem that requires attention [158].

3.2. HA Scaffolds Combined with Pro-Angiogenic Growth Factors or Drugs to Promote Angiogenesis

It is common knowledge that secreting pro-angiogenic growth factors may induce angiogenesis. Among these, the common cytokines are: VEGF [141], fibroblast growth factor (FGF) [1], angiopoietin (Ang) [143], transforming growth factor (TGF) [148,159], and platelet-derived growth factor (PDGF) [160], among others. In order to induce vascularization, scholars have compounded VEGF on the scaffold or transfected the VEGF gene into BMMSCs to promote the secretion or sustained release of angiogenic factors [161,162]. Quinlan et al. [163] compounded VEGF-containing alginate microparticles (MPs) with COL/HA scaffolds. Long-term stable release of VEGF occurs for up to 35 days. The composite scaffold was implanted into the rat bone defect model. Eight weeks later, obvious angiogenesis was subjected to immunofluorescence staining. To ensure the spatial-temporal release of angiogenic growth factors, the gene encoding cytokines were transfected into seed cells. For example, BMSCs were transfected with lentiviral vectors (LV-pdgfb) and seeded on PLGA/nHA scaffolds. It was found that the expression of pdgfb and the angiogenesis-related genes vWF and VEGFR2 was significantly increased, and the formation of new bone and vessels was significantly increased in vivo [144]. Some drugs such as salvianolic acid B [164] can promote the release of VEGF and induce angiogenesis.

Abundant experimental evidence exists for the use of growth factors in promoting angiogenesis. However, there is still no gold standard for selecting cytokines, and different cytokines may promote angiogenesis at different degrees for different cells. Combined cytokine application is better than single application, and the specific mechanism of action is still unclear. Moreover, the regulation of vascular growth by angiogenic growth factors or cells remains an urgent issue to be resolved in tissue-engineered bone vascularization.

3.3. Microsurgical Techniques to Promote Angiogenesis

Revascularization through microsurgical techniques is also a method of vascularizing tissue-engineered bone. The most common techniques are the implantation of the vascular pedicle, the implantation of the arteriovenous ring, the implantation of the periosteal flap, the implantation of the muscular flap, and packing of the fascial flap [165,166].

Due to the presence of the blood supply outside the tissue-engineered bone, the regeneration of the internal blood vessels and the formation of the bones are promoted. Largo et al. [167] co-cultured vegf-transfecting rBMSCs with HA and placed them in the muscle of rabbits. After one week, MRI examination revealed increased tissue perfusion and generation of a dense capillary network in the graft. Vascular bone muscle flaps
with vascular peduncles can be obtained. Animal experiments also showed that the bone volume produced by the periosteum is greater than that of the muscle. Tissue engineered bone implanted in the periosteum can form new bones without exogenous growth factors. Consequently, some scholars have implanted tissue-engineered bone into the periosteum. Following the formation of new bone, the supplying arteries and veins were harvested together to obtain a vascularized bone flap [168]. Researchers have made tissue-engineered bone from porous HA compound bone marrow aspiration fluid and BMP2. It is wrapped in the periosteum and has been implanted in the large omentum of small pigs. Bone and angiogenesis can be seen at 8 to 16 weeks postoperatively, suggesting that the use of periosteum can promote bone formation with grafting. The large omentum is a bioreactor suitable for in vivo culture of tissue-engineered bone. Because of the large vascular supply, the resulting bone flap can replace autologous bone flap grafting [169]. Tatara et al. [170] mixed commercialized materials (15% HA and 85% β-TCP) with autologous bone in different proportions. The composite stent is first placed at the site of the rib defect in the sheep and in contact with the rib periosteum to promote formation of new bone. After nine weeks of implantation, tissue-engineered bone with intercostal arteries and venous vascular pedicles was obtained and implanted into the site of the mandible defect. After microvascular anastomosis and fixation, 3/3 of the animals survived after 12 weeks. This cell-free, factor-free strategy sheds light on the reconstruction of bone defects. However, the sample size of the study is small, and the graft bone did not play the role of load-bearing bone, so further in-depth research is needed. Winkler et al. [171] anastomosed naked mice cryptovenous arteriovenous, making it an arteriovenous vessel ring. Human adipose-derived stem cells (hADSCs), human umbilical vein endothelial cells (hUVECs), and HA after osteogenesis induction were implanted into the vascular ring. Significant vascular formation was observed. Creation of arteriovenous rings (AVs) and deep fascial flaps with vascular pedicles avoids the harvesting of the flap and has been used in large animal models [172] and humans [173]. Even so, it takes several months for the bone to become vascularized, which limits its clinical application.

Although numerous experimental studies have confirmed that the various methods mentioned above can promote the vascularization and osteogenesis of tissue-engineered bone, methods such as vascular bundle implantation, prefabricated vascularized muscle-skeletal flaps, and the use of fascial flaps or muscle flaps to wrap artificial bone not only require higher microsurgical techniques, but also have unclear indications. There are still many limitations to its clinical application.

4. Construction of Innervated Tissue Engineered Bone

Domestic and foreign studies have found that nerve growth is parallel to bone growth and development [174]. Nerves are also closely associated with mature bones. There exists a rich neural network in the periosteum that is distributed in the Haversian system [175]. The nerves are distributed in some areas of active bone metabolism, such as the bone marrow, periosteum, and epiphysis. Coupaud et al. [176] found that the bone mineral density of the tibia, femoral cortex, and trabecular bone decreased significantly after a one-year follow-up in patients with spinal cord injury. These studies suggest that nerves have a significant influence on bone development and metabolism.

Nerve fibers of the innervating bone are divided into sympathetic and sensory nerves, which regulate the bone environment and osteocytes through neurotransmitters [177]. Our previous studies confirmed that sympathetic nerves play a negative regulatory role. Tensile stress promotes the detachment of local BMSCs from sympathetic/endothelial cell-based stem cell niches and migration to the osteogenic front through chemokines such as SDF-1 [178]. Sensory neurons play a key role in regulating bone homeostasis. Their injury results in decreased new bone formation and enhanced bone resorption, ultimately leading to increased bone fragility [179]. Nerve growth factor (NGF) can promote mandibular sensory nerve recovery and bone regeneration during distraction osteogenesis [180]. Sensory nerves play an important role in bone regeneration and reconstruction. Sensory nerves regulate
bone homeostasis through secreting neurotransmitters, which include NGF, calcitonin gene-related peptide (CGRP), substance P (SP), and semaphorin 3A (Sema3A) [181]. These neurotransmitters bind to receptors on the cell membrane of mesenchymal stem cells to regulate cell migration to the osteogenic front and promote osteogenesis.

When an autologous bone graft is used to reconstruct jaw defects, severe osteoporosis occurs in the grafted bone. Even if vascular anastomosis is performed to ensure sufficient blood supply, osteoporosis still happens. This phenomenon indicates that the internal environment of the grafted bone may be controlled by systemic factors other than blood supply. In our previous study, we developed an innervated bone graft by dissecting and anastomosing the nerves of the donor and recipient. Retrospective and prospective clinical studies have shown that simultaneous innervated bone grafting can significantly reduce osteoporosis and effectively maintain lower lip sensation. It also suggests that nerves are important in bone homeostasis [182,183]. In recent years, studies in the field of tissue engineering have found that in addition to vascularization, neurogenesis may also be important in promoting the formation of bone [167,184,185].

Neural stem cells (NSC) and NGFs were loaded on silk-HA composite scaffolds. After three days, the gene expressions of NSC marker Nestin and differentiated neuron markers Tubulin β3 (Tubb3) and microtubule-associated protein 2 (MAP2) were observed by qPCR (quantitative polymerase chain reaction). There was no statistical difference in Nestin’s expression when compared with the untreated nerve growth factor group, but Tubb3 and MAP2 were significantly higher than the control group. NGF is proposed to be an important factor in neurogenesis [186]. Coincidently, some researchers used CS/HA scaffolds loaded with NGF in the mandibular canine–molar region. NGF-loaded scaffolds were found to regulate gene levels related to NGF, osteogenic differentiation, and neurogenic differentiation. NGF significantly induces osseointegration and neuronal regeneration [187]. Liu et al. [188] designed a HA membrane enriched with nanocellulose to induce the differentiation of MSCs into osteoblasts and neuronal cells in vitro. Bioactive tissue-engineered bone containing osteoblasts, neuronal cells, and endothelial cells was also simulated in vitro. And through heterotropic osteogenesis, the rapid formation of blood vessels, nerve fibers, and new bone was found. There was evidence that the membrane can be used to induce the differentiation of MSCs, which has a good prospective application in bone tissue engineering. Cui et al. [189] implanted tissue-engineered bone with a vascular bundle and sensory nerve tract in two separate groups, and simple tissue-engineered bone was used as control. Following the implantation into the femoral defect of rabbits, the expressions of calcitonin gene related peptide (CGRP) and neuropeptide Y (NPY) were observed by immunohistochemical staining. The expression of CGRP and NPY in the tissue-engineered bone implanted with vascular bundles alone was higher than in the nerve bundle implantation group at three months. At 6 to 12 months, there was no significant difference in their expressions between the two groups, and they were all higher than those in the control group. Some scholars have also implanted sensory nerve bundles and motor nerve bundles into tissue-engineered bone to repair femoral defects in rabbits. The bone mineral density (BMD) test at 12 weeks after surgery showed that the bone defect in the sensory nerve tract implantation group was well repaired, and the BMD value was higher than that in the motor nerve tract implantation group and tissue-engineered bone control group [190]. In addition, the research team also found that Schwann cells can specifically promote BMSCs-derived endothelial cells to generate blood vessels, providing a cytological basis for neural tissue-engineered bone construction [191]. Implanted sensory nerve fibers can quickly grow into the scaffolds, increasing the expression of neurotransmitters such as CGRP [185]. Implantation of vascular bundles or sensory nerve bundles can significantly enhance the vascularization and neurotization of tissue-engineered bone for better osteogenesis [175,184].

The importance of sensory nerves in bone physiology and the regulation of the bone repair process indicate the correlation between sensory nerves and bone. Nerve tissue-engineered bone has good potential for application in the development of large-scale bone
repair. Since the nerve distribution and mechanism of action in normal bone tissue are not yet clear, further research in basic medicine is required. In addition, the research on neutralizing tissue-engineered bone is still in the animal experiment stage, and its clinical application needs to be further explored.

5. HA Composite Commercial Products

Collagraft® is a clinical alternative to autologous bone grafting. It is primarily a mixture of HA and β-TCP (13:7, mass ratio) with the addition of highly purified Col-I and prepared in a sterile lyophilized solution. In sheep lumbar models, Collagraft® with or without bone marrow produced new bone with mechanical properties similar to those of autologous bone grafting and with higher BMD [192]. When combined with syvium-derived stem cells (SDSCs), fibrin glue, and poly (glycolic acid) (PGA), Collagraft® can also be used to repair cartilage defects [193]. When combined with antibiotics, Collagraft® maintains 73% vancomycin activity and 61% gentamicin activity, and releases 432µg/mL vancomycin or 301µg/mL gentamicin within 48 h [194], making it suitable for topical delivery of antibiotics to prevent infection. In addition, compared with OsteoSet® (calcium sulfate), ProOsteon® (ceramics), and DBX® (demineralized bone matrix), Collagraft® has a stronger ability to induce bone remodeling and bone tissue regeneration [195,196]. Especially when combined with bone marrow, osteogenesis is more obvious [197]. A prospective randomized controlled clinical study of 267 patients with long bone fractures found that Collagraft® showed the same efficacy as autogenous iliac graft in the treatment of acute long bone fractures over 6–12 months [198]. However, other studies have shown that Collagraft® is not effective at inducing osteogenesis. Osteoid formation was found in 80% (4/5) of HA-TCP scaffolds with adipose-derived adult stem cells (ADAS) compared to 20% (1/5) of Collagraft® loaded with ADAS. 100% (3/3) of the HA-TCP implants loaded with hFOB 1.19 cells formed osteoid, compared to only 1/3 in Collagraft®, and significant adipose tissue was found in the Collagraft® [199]. Collagraft®, approved for the treatment of acute long bone fractures, healed significantly less than autogenous cancellous bone in a spinal fusion model, which suggests that clinicians should carefully consider using Collagraft® for spinal fusion [200].

Ossceram® Nano is a safe, absorbable bone replacement material composed of HA and β-TCP (3:2, mass ratio). β-TCP was rapidly decomposed while HA was not easily degraded. As a result, Ossceram® Nano has more ions released into the environment at the early stage of implantation compared to HA alone, allowing more collagen fiber colonization and promoting new bone maturation [201]. In addition, Ossceram® Nano has a microporous structure that facilitates ion exchange, a macroporous structure that facilitates cell colonization and vascular growth, and a nanostructure that supports bone formation [201], making it an effective bone substitute material.

Geistlich Bio-Oss® is a high-purity HA-based biological material extracted from natural bovine bone, which is widely used for alveolar bone defects, increasing bone mass before dental implants, and repairing craniofacial bone defects [202–205]. Bio-Oss® exhibits an inorganic composition and porous structure similar to human cancellous bone, facilitating the formation and growth of new bone.

Several other commercial HA composites are listed in Table 4. Although some clinical studies have reported the efficacy of commercialized HA composites as an alternative product for bone grafting, most of these studies have been observational, and high-quality randomized controlled studies are still needed.
Table 4. The name, character, and composition of some HA composite products.

| Products          | Character            | Composition                          | Porosity | Disadvantages | Ref.     |
|-------------------|----------------------|--------------------------------------|----------|---------------|----------|
| TricOs T®         | Synthetic complex    | 60% (m/m) HA, 40% (m/m) β-TCP; fibrin matrix | 80%      | NA            | [206,207]|
| NanoBone®         | Synthetic complex    | HA embedded in silica matrix         | 61%      | NA            | [208,209]|
| Straumann® Boneceramic | Synthetic complex   | 60% (m/m) HA, 40% (m/m) β-TCP       | 90%      | When the BoneCeramic® was used as the preservation for the alveolar bone, the new bone formation contained connective tissue and less bone, which may impair the stability of the implant. | [210–213]|
| Maxresorb®        | Synthetic complex    | 60% (m/m) HA, 40% (m/m) β-TCP       | 67.5%    | NA            | [210]    |
| MBCP®             | Synthetic complex    | 60% (m/m) HA, 40% (m/m) β-TCP       | 58%      | NA            | [214]    |
| PBCP®             | Synthetic complex    | 20% (m/m) HA, 80% (m/m) β-TCP       | 76%      | NA            | [214]    |
| OsteoFlux®        | Synthetic complex    | TCP/HA                               | 50–65%   | NA            | [215]    |
| TCH®              | Synthetic complex    | -                                    | 60.3–63.7% | NA            | [216]    |
| CopiOs®           | Xenograft substitutes| -                                    | 65.3–82.4% | NA            | [216]    |
| NuOss®            | Xenograft substitutes| -                                    | 80%      | NA            | [217]    |
| Osteobial®        | Xenograft substitutes| -                                    | 33.1%    | NA            | [217]    |
| Lubboc®           | Xenograft substitutes| -                                    | 67.3–82.5% | NA            | [216]    |
| Smartbone®        | Xenograft substitutes| -                                    | 27%      | NA            | [217]    |
| Cerabone®         | Xenograft substitutes| -                                    | 69.0%    | NA            | [208,210,218]|
| Maxgraft®         | Allograft substitutes| -                                    | -        | NA            | [208]    |
| Osteopure®        | Allograft substitutes| -                                    | 76.7–82.2% | NA            | [216]    |
| Puros®            | Allograft substitutes| -                                    | -        | NA            | [219]    |

Ref-reference; NA—not available.

6. Conclusions

Over the past few years, bone tissue engineering technology has expanded rapidly. HA occupies an irreplaceable position in scaffolds due to its good mechanical strength and biocompatibility. As mentioned above, in order to achieve a better osteogenic effect, HA composite scaffolds can be developed to be nearly similar to the composition and mechanical strength of natural bone. The ideal compressive strength is 2–230 MPa, and the ideal elastic modulus is 0.05–30 GPa for HA composites, which matches with the natural bone. The surface morphology and pore diameter that best suit the differentiation of seed cells can be explored. In general, pore size above 50 μm facilitates the entry of cells and angiogenesis. Additionally, the rate of material degradation can be adjusted to match the rate of bone regeneration, which takes about 2–6 months. However, there are numerous fields that need further study: 1. Compared with the mechanical strength of the scaffold before implantation, dynamic changes of the strength after implantation deserve attention; 2. Optimizing the creation process and low temperature disinfection may help to prepare a scaffold with both a porous structure and excellent mechanical properties; 3. HA can be doped with metal dopants such as Mg$^{2+}$, Zn$^{2+}$, Sr$^{2+}$, etc., to improve their properties; 4. The interaction mechanism and the spatial-temporal release of multiple cytokines require further exploration. Hence, other demands for function make biomimetic tissue-engineered bone a hot topic. Biomimetic tissue-engineered bone is gradually approaching the qualities
of physiological bone, and some progress has been made in angiogenesis and neurogenesis. Regenerating blood vessels and nerves can not only serve as a guarantor of bone formation, but also provide tissue-engineered bone with sensory functions. There is no doubt that breakthroughs in vascularization and innervation will enhance the vitality and prospects of tissue-engineered bone.

**Funding:** This study is supported by the National Natural Science Foundation of China (No. 81771046 and No. 81970907).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Dimitriou, R.; Jones, E.; McGonagle, D.; Giannoudis, P.V. Bone regeneration: Current concepts and future directions. BMC Med. 2011, 9, 66. [CrossRef] [PubMed]

2. Novais, A.; Chatzopoulou, E.; Chaussain, C.; Gorin, C. The Potential of FGF-2 in Craniofacial Bone Tissue Engineering: A Review. Cells 2021, 10, 932. [CrossRef] [PubMed]

3. Oberbarnscheidt, M.H.; Lakkis, F.G. Innate allorecognition. Immunol. Rev. 2014, 258, 145–149. [CrossRef] [PubMed]

4. Zhang, M.; Matinlinna, J.P.; Tsoi, J.K.H.; Liu, W.L.; Cui, X.; Lu, W.W.; Pan, H.B. Recent developments in biomaterials for long-bone segmental defect reconstruction: A narrative overview. J. Orthop. Transl. 2020, 22, 26–33. [CrossRef] [PubMed]

5. Kim, H.D.; Amirthalingam, S.; Kim, S.L.; Lee, S.S.; Rangasamy, J.; Hwang, N.S. Biomimetic Materials and Fabrication Approaches for Bone Tissue Engineering. Adv. Healthc. Mater. 2017, 6, 1700612. [CrossRef]

6. Oryan, A.; Monazzah, S.; Bigham-Sadegh, A. Bone Injury and Fracture Healing Biology. Biomed. Environ. Sci. 2015, 28, 57–71. [CrossRef] [PubMed]

7. Li, Z.; Meyers, C.A.; Chang, L.L.; Lee, S.; Li, Z.; Tomlinson, R.; Hoke, A.; Clemens, T.L.; James, A.W. Fracture repair requires TrkA signaling by skeletal sensory nerves. J. Clin. Investig. 2019, 129, 5137–5150. [CrossRef]

8. Zha, Y.; Li, Y.W.; Lin, T.Y.; Chen, J.; Zhang, S.M.; Wang, J.L. Progenitor cell-derived exosomes endowed with VEGF plasmids enhance osteogenic induction and vascular remodeling in large segmental bone defects. Theranostics 2021, 11, 397–409. [CrossRef] [PubMed]

9. Tevlin, R.; McArdle, A.; Atashroo, D.; Walmsley, G.G.; Senarath-Yapa, K.; Zielins, E.R.; Paik, K.J.; Longaker, M.T.; Wan, D.C. Biomaterials for Craniofacial Bone Engineering. J. Dent. Res. 2014, 93, 1187–1195. [CrossRef]

10. Rosetti, L.; Parisi, V.; Petretta, M.; Cavallo, C.; Desando, G.; Bartolotti, I.; Grigolo, B. Scaffolds for Bone Tissue Engineering: State of the art and new perspectives. Mat. Sci. Eng. C Mater. 2017, 78, 1246–1262. [CrossRef]

11. Wang, X.Y.; Zhu, Z.L.; Xiao, H.Z.; Luo, C.Q.; Luo, X.J.; Lv, F.R.; Liao, J.Y.; Huang, W. Three-Dimensional, MultiScale, and Interconnected Trabecular Bone Mimic Porous Tantalum Scaffold for Bone Tissue Engineering. ACS Omega 2020, 5, 22520–22528. [CrossRef] [PubMed]

12. Le Clainche, T.; Linklater, D.; Wong, S.; Le, P.; Juodkazis, S.; Le Guevel, X.; Coll, J.L.; Ivanova, E.P.; Martel-Frachet, V. Mechano-Bacterialic Titanium Surfaces for Bone Tissue Engineering. ACS Appl. Mater. Inter. 2020, 12, 48272–48283. [CrossRef] [PubMed]

13. Du, X.Y.; Wei, D.X.; Huang, L.; Zhu, M.; Zhang, Y.P.; Zhu, Y.F. 3D printing of mesoporous bioactive glass/silk fibroin composite scaffolds for bone tissue engineering. Mat. Sci. Eng. C Mater. 2019, 103, 109731. [CrossRef] [PubMed]

14. Montalbano, G.; Borciani, G.; Pontremoli, C.; Ciapetti, G.; Mattioli-Belmonte, M.; Fierilli, S.; Vitale-Brovarone, C. Development and Biocompatibility of Collagen-Based Composites Enriched with Nanoparticles of Strontium Containing Mesoporous Glass. Materials 2019, 12, 3719. [CrossRef] [PubMed]

15. Ansari, S.; Sami, N.; Yasin, D.; Ahmad, N.; Fatma, T. Biomedical applications of environmental friendly poly-hydroxyalkanoates. Int. J. Biol. Macromol. 2021, 183, 549. [CrossRef]

16. Dwivedi, R.; Pandey, R.; Kumar, S.; Mehrrota, D. Poly hydroxyalkanoates (PHA): Role in bone scaffolds. J. Oral Biol. Craniofac. Res. 2020, 10, 389–392. [CrossRef]

17. Tatara, A.M.; Koons, G.L.; Watson, E.; Piepergerdes, T.C.; Shah, S.R.; Smith, B.T.; Shum, J.; Melville, J.C.; Hanna, I.A.; Demian, N.; et al. Biomaterials-aided mandibular reconstruction using in vivo bioreactors. Proc. Natl. Acad. Sci. USA 2019, 116, 6954–6963. [CrossRef] [PubMed]

18. Glab, M.; Kudlacik-Kramarczyk, S.; Drabczyk, A.; Walter, J.; Kordyka, A.; Godzierski, M.; Bogucki, R.; Tyliszczak, B.; Sobczak-Kupiec, A. Hydroxyapatite Obtained via the Wet Precipitation Method and PVP/PVA Matrix as Components of Polymer-Ceramic Composites for Biomedical Applications. Molecules 2021, 26, 4268. [CrossRef]

19. Wang, Z.; Wang, J.; Ayarza, J.; Steeves, T.; Hu, Z.Y.; Manna, S.; Esser-Kahn, A.P. Bio-inspired mechanically adaptive materials through vibration-induced crosslinking. Nat. Mater. 2021, 20, 869. [CrossRef] [PubMed]
20. Kavasi, R.M.; Coelho, C.C.; Platania, V.; Quadros, P.A.; Chatzinikolaidou, M. In Vitro Biocompatibility Assessment of Nano-Hydroxyapatite. *Nanomaterials* 2021, 11, 1132. [CrossRef] [PubMed]

21. Li, M.; Xiong, P.; Yan, F.; Li, S.J.; Ren, C.H.; Yin, Z.C.; Li, A.; Li, H.F.; Ji, X.M.; Zheng, Y.F.; et al. An overview of graphene-based hydroxyapatite composites for orthopedic applications. *Bioact. Mater.* 2018, 3, 1–18. [CrossRef] [PubMed]

22. Luz, E.P.C.G.; Chaves, P.H.S.; Vieira, L.D.P.; Ribeiro, S.F.; Borges, M.D.; Andrade, F.K.; Muniz, C.R.; Infantes-Molina, A.; Rodriguez-Castellon, E.; Rosa, M.D.; et al. In vitro degradability and bioactivity of oxidized bacterial cellulose-hydroxyapatite composites. *Carbohydr. Polym.* 2020, 237, 116174. [CrossRef] [PubMed]

23. Fang, J.; Li, P.F.; Lu, X.; Fang, L.M.; Lu, X.Y.; Ren, F.Z. A strong, tough, and osteoconductive hydroxyapatite mineralized polycarboxylate/dextran hydrogel for bone tissue regeneration. *Acta Biomater.* 2019, 88, 503–513. [CrossRef] [PubMed]

24. Gautam, S.; Sharma, C.; Purohit, S.D.; Singh, H.; Dinda, A.K.; Poldar, P.D.; Chou, C.F.; Mishra, N.C. Gelatin-polycaeprolactone-nanohydroxyapatite electrosprun nanocomposite scaffold for bone tissue engineering. *Mat. Sci. Eng. C Mater.* 2021, 119, 11588. [CrossRef]

25. Sadeghi, M.; Bakhshandeh, B.; Dehghan, M.M.; Mehrnia, M.R.; Khojasteh, A. Functional synergy of anti-mir221 and nanohydroxyapatite scaffold in bone tissue engineering of rat skull. *J. Mater. Sci. Mater. M.* 2016, 27, 132. [CrossRef]

26. An, S.H.; Matsumoto, T.; Miyajima, H.; Nakahira, A.; Kim, K.H.; Imazato, S. Porous zirconia/hydroxyapatite scaffolds for bone reconstruction. *Dent. Mater.* 2012, 28, 1221–1231. [CrossRef] [PubMed]

27. Kim, C.; Lee, J.W.; Heo, J.H.; Park, C.; Kim, D.H.; Yi, G.S.; Kang, H.C.; Jung, H.S.; Shin, H.; Lee, J.H. Natural bone-mimicking nanopore-incorporated hydroxyapatite scaffolds for enhanced bone tissue regeneration. *Biomater. Res.* 2022, 26, 7. [CrossRef]

28. Motamedian, S.R.; Hosseinpour, S.; Ahsaie, M.G.; Khojasteh, A. Smart scaffolds in bone tissue engineering: A systematic review of literature. *World J. Stem. Cells* 2015, 7, 657–668. [CrossRef]

29. Kuttappan, S.; Mathew, D.; Nair, M.B. Biomimetic composite scaffolds containing bioceramics and collagen/gelatin for bone tissue engineering—A mini review. *Int. J. Biol. Macromol.* 2016, 93, 1390–1401. [CrossRef] [PubMed]

30. Qiu, Z.Y.; Cui, Y.; Tao, C.S.; Zhang, Z.Q.; Tang, P.F.; Mao, K.Y.; Wang, X.M.; Cui, F.Z. Mineralized Collagen: Rationale, Current Status, and Clinical Applications. *Materials* 2015, 8, 4733–4750. [CrossRef]

31. Olszta, M.J.; Cheng, X.G.; Lee, S.S.; Kumar, R.; Kim, Y.Y.; Kaufman, M.J.; Douglas, E.P.; Gower, L.B. Bone structure and formation: A new perspective. *Mat. Sci. Eng. R* 2007, 58, 77–116. [CrossRef]

32. Wang, J.C.; Liu, C.Z. Biomimetic Collagen/Hydroxyapatite Composite Scaffolds: Fabrication and Characterizations. *J. Bionic. Eng.* 2014, 11, 600–609. [CrossRef]

33. Zhou, C.C.; Ye, X.J.; Fan, Y.J.; Ma, L.; Tan, Y.F.; Qing, F.Z.; Zhang, X.D. Biomimetic fabrication of a three-level hierarchical calcium phosphate/collagen/hydroxyapatite scaffold for bone tissue engineering. *Biofabrication* 2014, 6, 035013. [CrossRef]

34. Cheng, W.N.; Ding, Z.Z.; Zheng, X.; Lu, Q.; Kong, X.D.; Zhou, X.Z.; Lu, G.Z.; Kaplan, D.L. Injectable hydrogel systems with improved biophysical and biochemical cues for bone regeneration. *Biomater. Sci.* 2020, 8, 2537–2548. [CrossRef]

35. Henkel, J.; Woodruff, M.A.; Epari, D.R.; Steck, R.; Glatt, V.; Dickinson, I.C.; Choong, P.F.M.; Schuetz, M.A.; Hutmacher, D.W. Bone Regeneration Based on Tissue Engineering Conceptions—A 21st Century Perspective. *Bone Res.* 2013, 1, 216–248. [CrossRef] [PubMed]

36. Rezwan, K.; Chen, Q.Z.; Blaker, J.J.; Bocaccini, A.R. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. *Biomaterials* 2006, 27, 3413–3431. [CrossRef]

37. Chen, P.Y.; McKittrick, J. Compressive mechanical properties of demineralized and deproteinized cancellous bone. *J. Mech. Behav. Biom.* 2011, 4, 961–973. [CrossRef] [PubMed]

38. Lee, S.; Porter, M.; Wasko, S.; Lau, G.; Chen, P.Y.; Novitskaya, E.E. Potential bone replacement materials prepared by two methods. *Materials Research Society symposia proceedings*. *Mater. Res. Soc. 2012, 1018, 178–181*. [CrossRef]

39. Feng, C.; Xue, J.M.; Yu, X.P.; Zhai, D.; Lin, R.C.; Zhang, M.; Xia, L.G.; Wang, X.Y.; Yao, Q.Q.; Chang, J.; et al. Co-inspired hydroxyapatite-based scaffolds for vascularized bone regeneration. *Acta Biomater.* 2021, 119, 419–431. [CrossRef] [PubMed]

40. Zhang, Y.M.; Wang, J.R.; Ma, Y.M.; Han, B.; Niu, X.J.; Liu, J.C.; Gao, L.; Wang, J.; Zhai, X.Y.; Chu, K.B.; et al. Preparation of poly(lactic acid)/sintered hydroxyapatite composite biomaterial by supercritical. *COBio-Med.* *Mater. Eng.* 2018, 29, 67–79. [CrossRef]

41. Stasny, P.; Sedlacek, R.; Suchy, T.; Lukasova, V.; Rampichova, M.; Trunec M. Structure degradation and strength changes of sintered calcium phosphate bone scaffolds with different phase structures during simulated biodegradation in vitro. *Mat. Sci. Eng. C Mater.* 2019, 100, 544–553. [CrossRef]

42. Uswatta, S.P.; Okeke, I.U.; Jayasuriya, A.C. Injectable porous nano-hydroxyapatite/chitosan/tripolyphosphate scaffolds with improved compressive strength for bone regeneration. *Mater. Sci. Eng. C Mater. Biol. Appl.* 2016, 69, 505–512. [CrossRef] [PubMed]

43. Kim, H.L.; Jung, G.Y.; Yoon, J.H.; Han, J.S.; Park, Y.J.; Kim, D.G.; Zhang, M.Q.; Kim, D.J. Preparation and characterization of nano-sized hydroxyapatite/alginate/chitosan composite scaffolds for bone tissue engineering. *Mater. Sci. Eng. C Mater. Biol. Appl.* 2015, 54, 20–25. [CrossRef]

44. Zheng, J.B.; Zhao, H.Y.; Dong, E.C.; Kang, J.F.; Liu, C.Z.; Sun, C.N.; Li, D.C.; Wang, L. Additively-manufactured PEEK/HA porous scaffolds with highly-controllable mechanical properties and excellent biocompatibility. *Mat. Sci. Eng. C Mater.* 2021, 128, 112333. [CrossRef]
70. Tan, J.; Saltzman, W.M. Biomaterials with hierarchically defined micro- and nanoscale structure. *Biomaterials* **2004**, *25*, 3593–3601. [CrossRef]
71. Kim, J.W.; Han, Y.S.; Lee, H.M.; Kim, J.K.; Kim, Y.J. Effect of Morphological Characteristics and Biomineralization of 3D-Printed Gelatin/Hyaluronic Acid/Hydroxyapatite Composite Scaffolds on Bone Tissue Regeneration. *Int. J. Mol. Sci.* **2021**, *22*, 6794. [CrossRef] [PubMed]
72. Xia, L.G.; Lin, K.L.; Jiang, X.Q.; Fang, B.; Xu, Y.J.; Liu, J.Q.; Zeng, D.L.; Zhang, M.L.; Zhang, X.L.; Chang, J.; et al. Effect of nano-structured bioceramic surface on osteogenic differentiation of adipose derived stem cells. *Biomaterials* **2014**, *35*, 8514–8527. [CrossRef] [PubMed]
73. Zhou, K.; Yu, P.; Shi, X.J.; Ling, T.X.; Zeng, W.N.; Chen, A.J.; Yang, W.; Zhou, Z.K. Hierarchically Porous Hydroxyapatite Hybrid Scaffold Incorporated with Reduced Graphene Oxide for Rapid Bone Ingrowth and Repair. *ACS Nano* **2019**, *13*, 9595–9606. [CrossRef]
74. Li, T.T.; Zhang, Y.; Ren, H.T.; Peng, H.K.; Lou, C.W.; Lin, J.H. Two-step strategy for constructing hierarchical pore structured chitosan-hydroxyapatite composite scaffolds for bone tissue engineering. *Carbohydr. Polym.* **2021**, *260*, 117765. [CrossRef] [PubMed]
75. Dou, Y.C.; Huang, J.H.; Xia, X.; Wei, J.W.; Kou, J.; Zou, Q.; Zuo, Y.; Li, J.D.; Li, Y.B. A hierarchical scaffold with a highly pore-interconnective 3D printed PLGA/n-HA framework and an extracellular matrix like gelatin network filler for bone regeneration. *J. Mater. Chem. B* **2021**, *9*, 4488–4501. [CrossRef]
76. Sztukiewicz, K.; Wlodarczyk, M.; Gazinska, M.; Rudnicka, K.; Plocinski, P.; Szymczyk-Ziolkowska, P.; Ziolkowski, G.; Biernat, M.; Sieja, K.; Grzymajlo, M.; et al. The Effect of Pore Size Distribution and L-Lysine Modified Apatite Whiskers (HAP) on Osteoblast Response in PLLA/HAP Foam Scaffolds Obtained in the Thermally Induced Phase Separation Process. *Int. J. Mol. Sci.* **2021**, *22*, 3607. [CrossRef]
77. Lee, D.J.; Kwon, J.; Kim, Y.I.; Wang, X.Y.; Wu, T.J.; Lee, Y.T.; Kim, S.; Miguez, P.; Ko, C.C. Effect of pore size in bone regeneration using polydopamine-laced hydroxyapatite calcium silicate scaffolds fabricated by 3D mould printing technology. *Orthod. Craniofac. Res.* **2019**, *22*, 127–133. [CrossRef]
78. Zhang, Q.H.; Schmelzer, E.; Gerlach, J.C.; Netteship, I. A microstructural study of the degradation by 3D and calcium release from hydroxyapatite-calcium oxide ceramics made by infiltration. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2017**, *73*, 684–691. [CrossRef]
79. Shuai, C.J.; Yang, W.J.; Peng, P.; Peng, S.P.; Pan, H. Accelerated degradation of HAP/PLLA bone scaffold by PGA blending facilitates bioactivity and osteoconductivity. *Bioact. Mater.* **2021**, *6*, 490–502. [CrossRef]
80. Wang, Y.P.; Yang, X.; Gu, Z.P.; Qin, H.H.; Li, L.; Liu, J.W.; Yu, X.X. In vitro study on the degradation of lithium-doped hydroxyapatite for bone tissue engineering scaffold. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2016**, *66*, 185–192. [CrossRef]
81. Chang, H.Y.; Tuan, W.H.; Lai, P.L. Biphasic ceramic bone graft with biphasic degradation rates. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2021**, *118*. [CrossRef]
82. Su, W.; Ma, X.M.; Sun, Z.; Yi, Z.; Cui, X.X.; Chen, G.C.; Chen, X.Y.; Guo, B.; Li, X.D. RhBMP-2 and concomitant rapid material degradation synergistically promote bone repair and regeneration with collagen-hydroxyapatite nanocomposites. *J. Mater. Chem. B* **2018**, *6*, 4338–4350. [CrossRef]
83. Li, X.Y.; Ma, B.J.; Li, J.H.; Shang, L.L.; Liu, H.; Ge, S.H. A method to visually observe the degradation-diffusion-reconstruction behavior of hydroxyapatite in the bone repair process. *Acta Biomater.* **2020**, *101*, 554–564. [CrossRef] [PubMed]
84. Li, H.L.; Li, L.L.; He, Y.Q.; Mao, W.; Ni, H.F.; Yang, A.L.; Lyu, F.Z.; Dong, Y.H. Wnt/beta-Catenin Pathway Balances Scaffold Degradation and Bone Formation in Tissue-Engineered Laminae. *Stem. Cells Int.* **2021**, *2021*, 8359582. [CrossRef]
85. Fayyazbakhsh, F.; Solati-Hashjin, M.; Keshtkar, A.; Shokrgozar, M.A.; Dehghan, M.M.; Larijani, B. Novel layered double hydroxides-hydroxyapatite/gelatin bone tissue engineering scaffolds: Fabrication, characterization, and in vivo study. *Mat. Sci. Eng. C Mater. Biol. Appl.* **2017**, *76*, 701–714. [CrossRef]
86. Yu, C.J.; Yang, W.J.; Feng, P.; Zou, Y.; Li, J.D.; Li, Y.B.; Wang, H.; Wang, J.C.; et al. Effect of pore structure on calcium hydroxyapatite degradation by 3D printing process. *Int. J. Biol. Macromol.* **2019**, *128*, 510–518. [CrossRef]
87. Zhang, P.B.; Wu, H.T.; Wu, H.; Lu, Z.W.; Deng, C.; Hong, Z.K.; Jing, X.B.; Chen, X.S. RGD-Conjugated Copolymer Incorporated into Composite of Poly(lactide-co-glycolide) and Poly(L-lactide)-Grafted Nanohydroxyapatite for Bone Tissue Engineering. *Biomacromolecules* **2011**, *12*, 2667–2680. [CrossRef]
88. Bhattacharjee, P.; Ahearn, M. Significance of Crosslinking Approaches in the Development of Next Generation Hydrogels for Corneal Tissue Engineering. *Pharmaceutics* **2021**, *13*, 319. [CrossRef]
89. Iglesias-Mejuto, A.; Garcia-Gonzalez, C.A. 3D-Printed, Dual Crosslinked and Sterile Aerogel Scaffolds for Bone Tissue Engineering. *Polymers* **2022**, *14*, 1211. [CrossRef]
90. Wang, Z.H.; Liu, H.; Luo, W.B.; Cai, T.Y.; Li, Z.H.; Liu, Y.Z.; Gao, W.N.; Wan, Q.; Wang, X.G.; Wang, J.C.; et al. Regeneration of skeletal system with genipin crosslinked biomaterials. *J. Tissue Eng.* **2020**, *11*, 2041731420974861. [CrossRef]
91. Lu, H.T.; Lu, T.W.; Chen, C.H.; Mi, F.L. Development of genipin-crosslinked and fucoidan-adsorbed nano-hydroxyapatite/hydroxypropyl chitosan composite scaffolds for bone tissue engineering. *Int. J. Biol. Macromol.* **2019**, *128*, 973. [CrossRef] [PubMed]
92. Panda, S.; Biswas, C.K.; Paul, S. A comprehensive review on the preparation and application of calcium hydroxyapatite: A special focus on atomic doping methods for bone tissue engineering. *Ceram. Int.* **2021**, *47*, 28122–28144. [CrossRef]
141. Chen, J.Y.; Tu, C.; Tang, X.Y.; Li, H.; Yan, J.Y.; Ma, Y.Z.; Wu, H.; Liu, C.X. The combinatory effect of sinusoidal electromagnetic field and VEGF promotes osteogenesis and angiogenesis of mesenchymal stem cell-laden PCL/HA implants in a rat subcritical cranial defect. Stem. Cell Res. Ther. 2019, 10. [CrossRef] [PubMed]

142. Li, J.L.; Cao, F.; Wu, B.; Yang, J.H.; Xu, W.W.; Wang, W.D.; Wei, X.W.; Liu, G.; Zhao, D.W. Immobilization of bioactive vascular endothelial growth factor onto Ca-deficient hydroxyapatite-coated Mg by covalent bonding using polydopamine. J. Orthop. Transl. 2021, 30, 82–92. [CrossRef] [PubMed]

143. Yin, J.; Gong, G.; Sun, C.; Yin, Z.Y.; Zhu, C.; Wang, B.; Hu, Q.; Zhu, Y.R.; Liu, X.H. Angiopoietin 2 promotes angiogenesis in tissue-engineered bone and improves repair of bone defects by inducing autophagy. Biomied. Pharm. 2018, 105, 932–939. [CrossRef]

144. Li, J.; Xu, Q.; Teng, B.; Yu, C.; Li, J.; Song, L.; Lai, Y.X.; Zhang, J.; Zheng, W.; Ren, P.G. Investigation of angiogenesis in bioactive 3-dimensional poly (D,L-lactide-co-glycolide)/nano-hydroxyapatite scaffolds by in vivo multiphoton microscopy in murine calvarial critical bone defect. Acta Biomater. 2016, 42, 389–399. [CrossRef] [PubMed]

145. McMillan, A.; Nguyen, M.K.; Gonzalez-Fernandez, T.; Ge, P.L.; Yu, X.H.; Murphy, W.L.; Kelly, D.J.; Alsberg, E. Dual non-viral gene delivery from microparticles within 3D high-density stem cell constructs for enhanced bone tissue engineering. Biomaterials 2018, 161, 240–255. [CrossRef] [PubMed]

146. Bhattacharjee, P.; Naskar, D.; Maiti, T.K.; Bhattacharya, D.; Kundu, S.C. Non-mulberry silk fibroin grafted poly (caprolactone)/nano hydroxyapatite nanofibrous scaffold for dual growth factor delivery to promote bone regeneration. J. Colloid Interface Sci. 2016, 472, 16–33. [CrossRef] [PubMed]

147. Dang, P.N.; Dwivedi, N.; Phillips, L.M.; Yu, X.H.; Herberg, S.; Bowerman, C.; Solorio, L.D.; Murphy, W.L.; Alsberg, E. Controlled Dual Growth Factor Delivery from Microparticles Incorporated Within Human Bone Marrow-Derived Mesenchymal Stem Cell Aggregates for Enhanced Bone Tissue Engineering via Endochondral Ossification. Stem. Cell Transl. Med. 2016, 5, 206–217. [CrossRef]

148. Dang, P.N.; Herberg, S.; Varghai, D.; Riazii, H.; Varghai, D.; McMillan, A.; Awadallah, A.; Phillips, L.M.; Jeon, O.; Nguyen, M.K.; et al. Endochondral Ossification in Critical-Sized Bone Defects via Reapprilantly Implantable Scaffold-Free Stem Cell Constructs. Stem. Cell Transl. Med. 2017, 6, 1644–1659. [CrossRef] [PubMed]

149. Shen, X.F.; Zhang, Y.X.; Gu, Y.; Xu, Y.; Liu, Y.; Li, B.; Chen, L. Sequential and sustained release of SDF-1 and BMP-2 from silk fibroin-nano hydroxyapatite scaffold for the enhancement of bone regeneration. Biomaterials 2016, 106, 205–216. [CrossRef] [PubMed]

150. Jarrar, H.; Altindal, C.; Gumusderioğlu, M. Scaffold-based osteogenic dual delivery system with melatonin and BMP-2 releasing PLGA microparticles. Int. J. Pharm. 2021, 600, 120489. [CrossRef] [PubMed]

151. Zhang, B.J.; He, L.; Han, Z.W.; Li, X.M.; Zhi, W.; Zheng, W.; Mu, Y.D.; Wang, W.D.; Wei, X.W.; Wang, W.D.; Wei, X.W.; Liu, G.; Zhao, D.W. Immobilization of bioactive vascular endothelial growth factor onto Ca-deficient hydroxyapatite-coated Mg by covalent bonding using polydopamine. J. Orthop. Transl. 2021, 30, 82–92. [CrossRef] [PubMed]

152. Dou, D.D.; Zhou, G.; Liu, H.W.; Zhang, J.; Liu, M.L.; Xiao, X.F.; Fei, J.J.; Guan, X.L.; Fan, Y.B. Sequential releasing of VEGF and BMP-2 from silk fibroin-nano hydroxyapatite scaffold for the enhancement of bone regeneration. Acta Biomater. 2016, 42, 389–399. [CrossRef] [PubMed]

153. Godoy-Gallardo, M.; Portoles-Gil, N.; Lopez-Periago, A.M.; Domingo, C.; Hosta-Rigau, L. Immobilization of BMP-2 and VEGF by mesenchymal stem cells and endothelial cells on calcium carbonate and hydroxylapatite scaffold in vivo. Int. J. Mol. Sci. 2017, 18, 240–255. [CrossRef]

154. Zhu, Y.H.; Cao, N.J.; Zhang, Y.; Cao, G.X.; Hao, C.P.; Liu, K.D.; Li, X.M.; Wang, W. The Ability and Mechanism of nHAC/CGF in inhibition of angiogenesis in vitro through the PI3K/Akt pathway. Zhonghua Yi Xue Za Zhi 2014, 95, 3061–3065. (In Chinese) [PubMed]
162. Piard, C.; Luthcke, R.; Kamalidinov, T.; Fisher, J. Sustained delivery of vascular endothelial growth factor from mesoporous calcium-deficient hydroxyapatite microparticles promotes in vitro angiogenesis and osteogenesis. *J. Biomed. Mater. Res. A* 2021, 109, 1080–1087. [CrossRef]

163. Quinlan, E.; Lopez-Noriega, A.; Thompson, E.M.; Hibbitts, A.; Cryan, S.A.; O’Brien, F.J. Controlled release of vascular endothelial growth factor from spray-dried alginate microparticles in collagen-hydroxyapatite scaffolds for promoting vascularization and bone repair. *J. Tissue Eng. Regen. M* 2017, 11, 1097–1109. [CrossRef]

164. Ji, C.L.; Bi, L.; Li, J.; Fan, J.J. Salvianolic Acid B-Loaded Chitosan/hydroxyapatite Scaffolds Promotes The Repair Of Segmental Bone Defect By Angiogenesis And Osteogenesis. *Int. J. Nanomed.* 2019, 14, 8271–8284. [CrossRef] [PubMed]

165. Fan, J.J.; Bi, L.; Jin, D.; Wei, K.H.; Chen, B.; Zhang, Z.Y.; Pei, G.X. Microsurgical Techniques Used to Construct the Vascularized and Neurotized Tissue Engineered Bone. *Biom. Res. Int.* 2014, 2014, 281872. [CrossRef] [PubMed]

166. Huang, R.L.; Kobayashi, E.; Liu, K.; Li, Q.F. Bone Graft Prefabrication Following the In Vivo Bioreactor Principle. *Ebiomedicine* 2016, 12, 43–54. [CrossRef]

167. Largo, R.D.; Burger, M.G.; Harschnitz, O.; Waschkies, C.F.; Grosso, A.; Scotti, C.; Kaempfen, A.; Gueven, S.; Jundt, G.; Scherberich, A.; et al. VEGF Over-Expression by Engineered BMSC Accelerates Functional Perfusion, Improving Tissue Density and In-Growth in Clinical-Size Osteogenic Grafts. *Front. Bioeng. Biotech.* 2020, 8, 755. [CrossRef]

168. Akar, B.; Tatar, A.M.; Sutradhar, A.; Hisiao, H.Y.; Miller, M.; Cheng, M.H.; Mikos, A.G.; Brey, E.M. Large Animal Models of an In Vivo Bioreactor for Engineering Vascularized Bone. *Tissue Eng. Part B Res.* 2018, 24, 317–325. [CrossRef]

169. Naujokat, H.; Lipp, M.; Acil, Y.; Wieler, H.; Birkenfeld, F.; Sengerbusch, A.; Bohrmann, F.; Wiltfang, J. Bone tissue engineering in the greater omentum is enhanced by a perioseal transplant in a miniature pig model. *Regen. Med.* 2019, 14, 127–138. [CrossRef]

170. Tatara, A.M.; Kretlow, J.D.; Spicer, P.P.; Lu, S.; Lam, J.; Liu, W.; Cao, Y.L.; Liu, G.P.; Jackson, J.D.; Yoo, J.J.; et al. Autologously Generated Tissue-Engineered Bone Flaps for Reconstruction of Large Mandibular Defects in an Ovine Model. *Tissue Eng. Pt. A* 2015, 21, 1520–1528. [CrossRef]

171. Winkler, S.; Mutschall, H.; Biggemann, J.; Fey, T.; Greil, P.; Korner, C.; Weisbach, V.; Meyer-Lindenberg, A.; Arkudas, A.; Horch, R.E.; et al. Human Umbilical Vein Endothelial Cell Support Bone Formation of Adipose-Derived Stem Cell-Loaded and 3D-Printed Osteogenic Matrices in the Arteriovenous Loop Model. *Tissue Eng. Pt. A* 2021, 27, 413–423. [CrossRef] [PubMed]

172. Kengelbach-Weigand, A.; Thielen, C.; Baueurle, T.; Goetzl, R.; Gerber, T.; Koerner, C.; Beier, J.P.; Horch, R.E.; Boos, A.M. Personalized medicine for reconstruction of critical-size bone defects—A translational approach with customizable vascularized bone tissue. *Npj. Regen. Med.* 2021, 6, 49. [CrossRef]

173. Horch, R.E.; Beier, J.P.; Kneser, U.; Arkudas, A. Successful human long-term application of in situ bone tissue engineering. *J. Cell Mol. Med.* 2014, 18, 1478–1485. [CrossRef]

174. Kjaer, I. Neurooesteology. *Ugeskr Laeger* 1998, 160, 1923–1926. [PubMed]

175. Zhao, J.; Levy, D. The sensory innervation of the calvarial periosteum is nociceptive and contributes to headache-like behavior. *Pain* 2014, 155, 1392–1400. [CrossRef] [PubMed]

176. Coupaud, S.; McLean, A.N.; Purcell, M.; Purser, M.; McCarthy, M.; Allan, D.B. Decrease in bone mineral density at cortical and trabecular sites in the tibia and femur during the first year of spinal cord injury. *Bone* 2015, 74, 69–75. [CrossRef] [PubMed]

177. Takahashi, N.; Matsuda, Y.; Sato, K.; de Jong, P.R.; Bertin, S.; Tabela, K.; Yamazaki, K. Neuronal TRPV1 activation regulates alveolar bone resorption via suppression of osteoclastogenesis via CGRP. *Sci. Rep.* 2016, 6, 29294. [CrossRef] [PubMed]

178. Wu, B.L.; Wang, L.; Yang, X.; Mao, M.; Ye, C.; Liu, P.; Yang, Z.H.; Yang, X.J.; Lei, D.L.; Zhang, C.P. Norepinephrine inhibits mesenchymal stem cell chemotaxis migration by increasing stromal cell-derived factor-1 secretion by vascular endothelial cells via NE/abrd3/JNK pathway. *Cell Res.* 2016, 34, 214–220. [CrossRef] [PubMed]

179. Kang, H.W.; Lee, S.J.; Ko, I.K.; Kengla, C.; Yoo, J.J.; Atala, A. A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. *Nat. Biotechnol.* 2016, 34, 312. [CrossRef]

180. Wang, L.; Cao, J.; Lei, D.L.; Cheng, X.B.; Zhou, H.Z.; Hou, R.; Zhao, Y.H.; Cui, F.Z. Application of nerve growth factor from spray-dried alginate microparticles in collagen-hydroxyapatite scaffolds for promoting vascularization and bone repair. *Front. Bioeng. Biotech.* 2016, 349, 317–325. [CrossRef] [PubMed]

181. Abdelrehem, A.; Shi, J.C.; Wang, X.D.; Wu, Z.Q.; Mashrah, M.A.; Zhang, C.Y.; Li, S.Y.; Zhang, C.P.; Wang, L. A novel loop neurorrhaphy technique to preserve lower lip sensate in mandibular reconstruction using an innervated vascularized iliac bone flap. *Head Neck J. Sci. Spec.* 2022, 44, 46–58. [CrossRef] [PubMed]

182. Fan, J.J.; Mu, T.W.; Qin, J.J.; Bi, L.; Pei, G.X. Different Effects of Implanting Sensory Nerve or Blood Vessel on the Vascularization, Neurotization, and Osteogenesis of Tissue-Engineered Bone In Vivo. *Biom. Res. Int.* 2014, 2014, 412570. [CrossRef] [PubMed]

183. Wu, Y.; Jing, D.; Ouyang, H.W.; Li, L.; Zhai, M.M.; Li, Y.; Bi, L.; Pei, G.X. Pre-implanted Sensory Nerve Could Enhance the Neurotization in Tissue-Engineered Bone. *Tissue Eng. Pt. A* 2015, 21, 2241–2249. [CrossRef]

184. Fitzpatrick, V.; Martin-Moldes, Z.; Deck, A.; Torres-Sanchez, R.; Valat, A.; Cairns, D.; Li, C.; Kaplan, D.L. Functionalized 3D-printed silk-hydroxyapatite scaffolds for enhanced bone regeneration with innervation and vascularization. *Biomaterials* 2021, 276, 120995. [CrossRef]
187. Yeh, J.; Huang, B.; Gong, P. Nerve growth factor-chondroitin sulfate/hydroxyapatite-coating composite implant induces early osseointegration and nerve regeneration of peri-implant tissues in Beagle dogs. J. Orthop. Surg. Res. 2021, 16, 51. [CrossRef] [PubMed]

188. Liu, F.; Wei, B.J.; Xu, X.Y.; Ma, B.J.; Zhang, S.; Duan, J.Z.; Kong, Y.; Yang, H.R.; Sang, Y.H.; Wang, S.H.; et al. Nanocellulose-Reinforced Hydroxyapatite Nanobelt Membrane as a Stem Cell Multi-Lineage Differentiation Platform for Biomimetic Construction of Bioactive 3D Osteoid Tissue In Vitro. Adv. Healthc. Mater. 2021, 10, e2001851. [CrossRef] [PubMed]

189. Cui, J.D.; Pei, G.X.; Jiang, S. A study of the different effect on the expression of calcitonin gene related peptide and neuropeptide Y in tissue-engineered bone with vascular bundle graft in vivo and that with sensory nerve tract graft in vivo. Zhonghua Wai Ke Za Zhi 2008, 46, 1249–1252. (In Chinese)

190. Jiang, S.; Liu, Y.; Wang, Q.; Zhao, P.; Mu, T.; Wang, L.; Qin, J.; Chen, S.; Pei, G. Experimental study on construction of neurotization tissue engineered bone for repairing large bone defects in rabbit. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2010, 24, 599–605. (In Chinese) [PubMed]

191. Zhang, X.X.; Jiang, X.R.; Jiang, S.; Cai, X.Y.; Yu, S.J.; Pei, G.X. Schwann cells promote prevascularization and osteogenesis of tissue-engineered bone via bone marrow mesenchymal stem cell-derived endothelial cells. Stem. Cell Res. Ther. 2012, 3, 182. [CrossRef] [PubMed]

192. Walsh, W.R.; Harrison, J.; Loeffler, A.; Martin, T.; Van Sickle, D.; Brown, M.K.C.; Sonnabend, D.H. Mechanical and histologic evaluation of Collagraft (R) in an ovine lumbar fusion model. Clin. Orthop. Relat. R 2000, 375, 258–266. [CrossRef] [PubMed]

193. Pei, M.; He, F.; Boyce, B.M.; Kish, V.L. Repair of full-thickness femoral condyle cartilage defects using allogenic synovial cell-engineered tissue constructs. Osteoarthr. Cartil. 2009, 17, 714–722. [CrossRef]

194. Heijink, A.; Yaszemski, M.J.; Patel, R.; Rouse, M.S.; Lewallen, D.G.; Hanssen, A.D. Local antibiotic delivery with OsteoSet (R), DBX (R), and Collagraft (R). Clin. Orthop. Relat. R. 2006, 451, 29–33. [CrossRef] [PubMed]

195. Chen, W.C.; Ju, C.P.; Tien, Y.C.; Lin, J.H.C. In vivo testing of nanoparticle-treated TTCP/DCPA-based ceramic surfaces. Acta Biomater. 2009, 5, 1767–1774. [CrossRef] [PubMed]

196. Leupold, J.A.; Barfield, W.R.; An, Y.H.; Hartsook, L.A. A comparison of ProOsteon, DBX, and Collagraft in a rabbit model. J. Biomed. Mater. Res. B 2006, 79, 292–297. [CrossRef] [PubMed]

197. Alvis, M.; Lalor, P.; Brown, M.K.C.; Thorn, M.R.; Block, J.E.; Hornby, S.; Berg, R.; Reddi, A.H. Osteoinduction by a collagen mineral composite combined with isologous bone marrow in a subcutaneous rat model. Orthopedics 2003, 26, 77–80. [CrossRef] [PubMed]

198. Cornell, C.N.; Lane, J.M.; Chapman, M.; Merkow, R.; Seligson, D.; Henry, S. Multicenter trial of Collagraft as bone graft substitute. J. Orthop. Trauma 1991, 4, 1–8. [CrossRef]

199. Hicok, K.C.; Du Laney, T.V.; Zhou, Y.S.; Halvorsen, Y.D.C.; Hitt, D.C.; Cooper, L.F.; Gimble, J.M. Human adipose-derived adult stem cells produce osteoid in vivo. Tissue Eng. 2004, 10, 371. [CrossRef] [PubMed]

200. Muschler, G.F.; Negami, S.; Hyodo, A.; Gaisser, D.; Easley, K.; Kambic, H. Evaluation of collagen ceramic composite graft materials in a spinal fusion model. Clin. Orthop. Relat. Res. 1996, 328, 250–260. [CrossRef]

201. de Val, J.E.M.S.; Calvo-Guirado, J.L.; Gomez-Moreno, G.; Gehrke, S.; Mazon, P.; de Aza, N. In vivo test of osteoinduction by collagen mineral composite combined with isologous bone marrow in a subcutaneous rat model. J. Orthop. Surg. Res. 2017, 12, 258–266. [CrossRef] [PubMed]

202. Li, C.C.; Bi, W.; Zhang, D.; Sang, Z.J.; Li, L.Q.; Yu, Y.C. Transforming growth factor-beta1 promotes Geistlich Bio-Oss (R) osteogenesis via inhibiting local inflammation response in vivo. Int. J. Clin. Exp. Patho. 2017, 10, 9310–9317. [CrossRef]

203. Martins, S.C.R.; Magrin, G.L.; Joly, J.C.; Benfatti, C.A.M.; Bianchini, M.A.; Peruzzo, D.C. Histologic and histomorphometric analysis of two biomaterials of xenogenous origin for maxillary sinus elevation: A pilot study. Quintessence Int. 2021, 52, 248–256. [CrossRef] [PubMed]
211. De Santis, E.; Lang, N.P.; Salata, L.A.; Pereira, F.P.; Favero, V.; Botticelli, D. Healing of Bone-Ceramic at buccal dehiscence defects at implants installed immediately into extraction sockets. An experimental study in dogs. *Clin. Oral Implant. Res.* 2016, 27, 1462–1468. [CrossRef] [PubMed]

212. Zhang, X.B.; Tiainen, H.; Haugen, H.J. Comparison of titanium dioxide scaffold with commercial bone graft materials through micro-finite element modelling in flow perfusion. *Med. Biol. Eng. Comput.* 2019, 57, 311–324. [CrossRef] [PubMed]

213. Tirkkonen, L.; Haimi, S.; Huttunen, S.; Wolff, J.; Pirhonen, E.; Sandor, G.K.; Miettinen, S. Osteogenic Medium Is Superior to Growth Factors in Differentiation of Human Adipose Stem Cells Towards Bone-Forming Cells in 3d Culture. *Eur. Cells Mater.* 2013, 25, 144. [CrossRef]

214. Seo, S.J.; Kim, Y.G. Improved bone regeneration using collagen-coated biphasic calcium phosphate with high porosity in a rabbit calvarial model. *Biomed. Mater.* 2021, 16, 015012. [CrossRef] [PubMed]

215. Carrel, J.P.; Wiskott, A.; Moussa, M.; Rieder, P.; Scherrer, S.; Durual, S. A 3D printed TCP/HA structure as a new osteoconductive scaffold for vertical bone augmentation. *Clin. Oral Implant. Res.* 2016, 27, 55–62. [CrossRef]

216. Arbez, B.; Kun-Darbois, J.D.; Convert, T.; Guillaume, B.; Mercier, P.; Hubert, L.; Chappard, D. Biomaterial granules used for filling bone defects constitute 3D scaffolds: Porosity, microarchitecture and molecular composition analyzed by microCT and Raman microspectroscopy. *J. Biomed. Mater. Res. B* 2019, 107, 415–423. [CrossRef] [PubMed]

217. Ortiz-Puigpelat, O.; Simoes, A.; Caballe-Serrano, J.; Hernandez-Alfaro, F. Blood absorption capacity of different xenograft bone substitutes. An in-vitro study. *J. Clin. Exp. Dent.* 2019, 11, e1018–e1024. [CrossRef] [PubMed]

218. Fabricky, M.M.C.; Gabor, A.G.; Milutinovici, R.A.; Watz, C.G.; Avram, S.; Drighici, G.; Mihali, C.V.; Moaca, E.A.; Dehelean, C.A.; Galuscan, A.; et al. Scaffold-Type Structure Dental Ceramics with Different Compositions Evaluated through Physicochemical Characteristics and Biosecurity Profiles. *Materials* 2021, 14, 2266. [CrossRef]

219. Moore, S.T.; Katz, J.M.; Zhukauskas, R.M.; Hernandez, R.M.; Lewis, C.S.; Supronowicz, P.R.; Gill, E.; Grover, S.M.; Long, N.S.; Cobb, R.R. Osteoconductivity and Osteoinductivity of Puros (R) DBM Putty. *J. Biomater. Appl.* 2011, 26, 151–171. [CrossRef]